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1. INTRODUCTION 
The earliest documented case of Osteogenesis Imperfecta (OI) dates back to 
1000 BC. Paleopathological analysis of the skeletal remains of an Egyptian 
mummy of a 3-day-old infant, has shown, that he was affected with severe 
lethal OI (i.e. skull and long bones deformities, Dentinogenesis Imperfecta (DI), 
thin bones) (Lowenstein, 2009; Tainmont, 2007). There are 1700 known, 
published works regarding bone brittleness, numerous fractures and bone 
deformity reporting in medical literature (Axmann, 1831; Ekman, 1788; Reiske, 
1776; Vrolik, 1849; Weil, 1981). For almost 300 years of OI medical history the 
disorder was described using various eponyms, which along with phenotype 
variety, presented difficulties for classifying OI cases as a single disease 
(Table 1) (Baljet, 2002; Weil, 1981). It was not until the late 1800’s that the 
common nature of brittle bone diseases under different eponyms was estab-
lished via histological analysis (Looser, 1906; Schmidt, 1897; Stilling, 1889). In 
1924 it was agreed that the OI bone phenotype was caused by abnormal 
collagen and disturbed osteoblast maintenance (Bauer, 1920; Knaggs, 1924). A 
majority of OI cases involve pathogenic mechanisms, altering collagen type I 
structure, synthesis, post-translational modifications, trafficking, processing and 
secretion (Marini et al., 2017). Collagen type I is the most abundant structural 
protein in the human organism, found in bone, teeth, lungs and blood vessels, 
thus symptoms of OI disturb not only bone tissues but many others including 
ligament, dentin and sclera (Van Dijk and Sillence, 2014). Since 1912 the 
famous classical triad of main OI characteristics has included: blue sclera, 
frequent fractures and deafness (Weil, 1981). Later, symptoms such as dental, 
cartilage and blood vessel defects were added (Bauer, 1940). The modern 
conception of OI is based on the works of David Sillence, who unified mild and 
severe bone fragility cases into a single picture of OI disorder, providing OI 
classification (Sillence, 1981; Sillence et al., 1979b; Sillence and Rimoin, 
1978).  
OI is a genetically and phenotypically heterogeneous disorder, thus the 
prevalence of OI depends on the OI type being considered, where milder OI 
forms are more prevalent compared to severe OI forms (Martin and Shapiro, 
2009). Studies in countries with extensive medical databases reported the preva-
lence of OI as occurring in 1.5/10,000 and 0.5/10,000 living births (Folkestad et 
al., 2016; Kuurila et al., 2002). Marini et al. proposed that the overall OI 
incidence as 1/10,000 (Marini et al., 2017). However, other researchers estimate 
OI prevalence as 1/20,000 (Van Dijk and Sillence, 2014). Collagen-related OI 
cases are thought to be distributed evenly among populations. However, there 
might be some differences among OI forms. For instance, the proportion of 
collagen type I pathogenic variants is higher in mild OI, compared to severe and 




Table 1. Eponyms of Osteogenesis Imperfecta (adapted from Weil 1981). 
Adair-Dighton disease (syndrome) Malacia myeloplastica 
Aplasia periostalis Maladie de Durante 
Blegvad-Haxthausen syndrome Micromelia annularis (chondromalacia) 
Blue sclera syndrome Molities ossium 
Blue sclerotics and brittle bones  
(fragility of bones) 
Osseous fragility 
Blue scleras and fragilitas ossium Osteogenesis imperfecta congenita (Vrolik) 
Brittle bones and blue sclerae Osteogenesis imperfecta (familiaris) (tarda) 
Dark sclerotics and fragilitas ossium Osteomalacia congenita 
Dysplasie periostale Osteomyopathia 
Dystrophie periostale Osteoporosis foetalis 
Eddowe disease (syndrome) Osteopsathyrosis idiopathica (Lobstein) 
Ekman syndrome Osteopsathyrosis (foetalis) (hereditaria) 
Ekman-Lobstein syndrome Ostitis parenchymatosa chronica 
Fetal rickets Rachitis congenita (foetalis annularis) 
Fragile bones, Fragility of the bones Spurway-Eddowes syndrome 
Hereditary fibrous osteodysplasia van der Hoeve syndrome 
Hereditary hypoplasia of the 
mesenchymez 
Vrolik disease (syndrome) 
Lobstein disease  
 
During the early stage of genetic research, OI was considered as a hereditary 
collagen type I disorder (Barsh and Byers, 1981; Brookes et al., 1989; Byers et 
al., 1988; Pope et al., 1985; Spotila et al., 1991; Wallis et al., 1986). It was 
concluded, that pathogenic variants in the collagen type I genes give rise to all 
OI types (Wallis et al., 1986). Interestingly, estimating the genotype-phenotype 
correlation in collagen-related OI is still challenging to a certain extent, as 
patients who harbor identical pathogenic variants develop phenotypes of 
different severity (Dalgleish, 1998).  
Understanding OI remained challenging, as the genetic cause of OI had not 
yet been identified in some patients. Surprisingly, these patients phenotypically 
resembled patients with classical COL1A1/2 pathogenic variants and Sillence 
OI types (Jay R. Shapiro et al., 2013). With the availability of next generation 
sequencing techniques (NGS) the involvement of other genes responsible for OI 
has been confirmed. Within a few years 10 non-collagen OI genes were 
elucidated (Asharani et al., 2012; Becker et al., 2011; Martínez-Glez et al., 
2012; Semler et al., 2012; van Dijk et al., 2012). An OI “gene rush”, which 
continues nowadays, changed modern conception of OI. In the beginning of the 
new century, OI stopped being considered as a strictly collagen-related disorder. 
OI is now classified into 19 different types according to genetic cause (Van Dijk 
and Sillence, 2014). 
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The present concept of OI includes: phenotypic and genetic heterogeneity, 
the absence of epidemiological differences based on sex and race (Marini et al., 
2017). However, knowledge about OI has grown exponentially during the past 
few years; many crucial aspects of the disorder remain unexplored and a cure 
still does not exist. Thus, there is a need for the further exploration of OI 
etiology, pathology and epidemiology persists.  
The current thesis addresses issue of spectrum of collagen type I pathogenic 
variants in 30 Estonian and 94 Ukrainian unrelated OI patients and describes 
novel COL1A1/2 OI pathogenic variants with correspondence to OI type for the 
first time. Further, this thesis explores de novo collagen type I pathogenic 
variants in 144 OI families in terms of genotype characteristics and phenotype 
severity. In addition, we investigate OI type V patients’ genotype and pheno-
type characteristics and evaluate genotype-phenotype correlations in 238 
unrelated OI patients. Finally, OI inter- and intrafamilial variability in collagen-
related OI families is analyzed.  
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2. REVIEW OF LITERATURE 
2.1. OI bone pathology 
OI bone is characterized by increased fragility, low bone mass and abnormalities 
in bone structure. These factors cause a susceptibility to fractures in OI patients 
(Marini et al., 2017). The latest research has shown that OI defect is complex, 
and both bone structure and function is altered in addition to the main patho-
logical mechanism of an OI pathogenic variant (Jay R. Shapiro et al., 2013). 
Notably, independent from causative pathogenic variant, general bone tissue 
properties are similar between different OI types (Marini et al., 2017). However, 
histological modifications correlate with the phenotypical severity of a disorder. 
Histological analysis describes OI bone as an immature, woven bone with an 
osteoporotic pattern. OI bone differs with a reduced amount of extracellular 
matrix (ECM), poor lamellar structure, thick osteoid, thin and chaotic trabecula, 
as well as decreased cortical bone mass (Baron et al., 1983). On a cellular level, 
OI bone shows hypercellularity and provides enhanced bone turnover and 
mineralization. However, ECM synthesis is decreased within measure of a single 
cell (Fratzl-Zelman et al., 2016; Rauch et al., 2000; Roschger et al., 2008). OI 
pathological mechanisms alter ECM not only via reduction of collagen levels 
but also the noncollagenous protein (NCP) level, revealing ECM qualitative 
differences of OI in addition to quantitative changes (Fedarko et al., 2009). 
Freedman et al. hypothesized that altered stoichiometry of collagen and NCPs 
are partly responsible for OI phenotypic variations (Freedman et al., 2000). 
 
 
2.1.1. OI molecular mechanisms 
The disruption of bone material properties in OI might be caused by several 
factors: collagen-related alterations (collagen structure and quantity, collagen 
processing, post-translational modifications, transport and chaperons); mine-
ralization defects, abnormal osteoblast function and differentiation; defective 
cell signaling and proliferation (Marini et al., 2017). A detailed description of 
molecular mechanisms of recessive OI are presented in section 2.4. 
 
 
2.1.1.1. Collagen type I alterations in OI 
Collagen type I is synthetized in the rough endoplasmic reticulum (ER) of 
osteoblasts, skin fibroblasts and tenocytes. COL1A1 and COL1A2 genes are 
transcribed into α1 and α2 chains. Collagen fiber consists of two α1 and one α2 
chains. These chains obtain a simple structure, where every third amino acid 
(aa) is glycine (Gly), forming Gly-Xaa-Yaa triplets, in which X and Y are any 




The collagen quantitative defect is caused by loss-of-function (LoF) pathogenic 
variants in the COL1A1/2 genes. These pathological variants are mostly re-
presented by splice site, nonsense and frameshift pathogenic variants. LoF 
pathogenic variants result in a severely truncated mRNA molecules include a 
premature termination stop codon activation (PTC), which is followed by the 
rescue mechanism of a mediated mRNA decay (NMD) (Chang et al., 2007; 
Fang et al., 2013; Symoens et al., 2014). As a result, develops haploinsuffi-
ciency and all collagen I chains are synthetized from one wild type allele. The 
collagen I amount is reduced by half. In general, phenotypes are represented 
with milder OI forms (Marini et al., 2007). 
Structural defects include: single nucleotide variants (SNV)s and substitution 
of one aa, which causes chain structure due to differences in charge and struc-
tural properties of aa; C-propeptide domain changes, which cause folding and 
transport delay; N-propeptide defects, which result in abnormal helix formation; 
aa deletions and duplications, which cause shift in chains of a heterotrimer 
(Cabral et al., 2003; Symoens et al., 2014). Structural defects cause a delay of 
procollagen folding (Symoens et al., 2014). Due to this, procollagen chains are 
overmodified and form atypical collagen fibrils (Marini et al., 2017). These 
abnormal fibrils result in disorganized ECM, ER stress, alterations of osteoblast 
differentiation and maturation. Structurally abnormal collagen is degraded. 
Abnormal heterotrimers are usually not incorporated into the matrix due to the 
selective deposition of collagen fibrils (Bateman and Golub, 1994; Cetta et al., 
1993). As a result, collagen synthesis is decreased and bone mass is reduced 
(Ishida et al., 2009). Collagen type I also indirectly affects mineralization pro-
cesses and cell maintenance via binding of vital NCPs, cells and bone proteins, 
essential for ECM formation (Jay R. Shapiro et al., 2013).  
Collagen structure defects are qualitative alterations of a collagen molecule. 
These changes are represented with missense pathogenic variants, causing 
substitution of aa (Prockop and Kivirikko, 1984). Clinical phenotype are affected 
by the character of the changes, location of substitution, altered aa types and 
defective chains (Marini et al., 2007). An altered aa ruins the proper organized 
 
Figure 1. Collagen structure (Marini et al., 2017). 
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structure of triple helix. (Martin and Shapiro, 2009; Millington-Ward et al., 
2005) (Figure 2). The most severe phenotypes arise due to changes of a Gly in 
Gly-Xaa-Yaa triplets with an aa with distant polarity, charge and structure (Glu, 
Arg, Asp, Val) (Figure 2c).  
Some of the pathogenic variant positions might alter major ligand binding 
domains (MLBR), which bind essential NCPs and bone cells. Thus, bone fragility 
results not only in a structural change of a collagen I, but also in its inability to 
fulfill its function (Marini et al., 2007). For example, lethal pathogenic variants 
are associated with the MLBR2 and MLBR3 domains (Cabral et al., 2003; 
Marini et al., 2007). Lethal domains also interrupt the proteoglycan binding sites 
(Kuivaniemi et al., 1997; Marini et al., 2007). Structural alterations are 
responsible for the whole spectrum of OI forms (types I–IV) (Marini et al., 2017; 
Patel and Camacho, 2019; Sillence et al., 1979a; Van Dijk and Sillence, 2014). 
Figure 2. (a) COL1A1 and COL1A2 genes’ structure. (b) Synthesis and assembly of a 
wild type and mutant collagen I with Glycine substitution (red hexagon) (Millington-
Ward et al., 2005). (c) Cross-section of a collagen triple helix (Gly-Xaa-Yaa)n. Gly 
residues – dark blue, X residues – dark grey, Y residues – light grey. The circle illustrates 
the diameter of a wild type triple helix. (c1) Normal, (c2) Gly substitution with Ser, (c3) 







2.1.1.2. Mineralization molecular defects  
A few OI cases arise due to pathogenic variants in genes that are involved in bone 
mineralization, among which is the IFITM5 gene, which codes bone-restricted 
interferon-induced transmembrane protein-like protein (BRIL). Alteration of 
this protein might result in excessive ossification and abnormal mineralization 
(Akiyama et al., 2010; Becker et al., 2011; Semler et al., 2012). The exact 
function of the BRIL protein is unknown; however, the participation of BRIL in 
bone development and mineralization has been hypothesized (Reich et al., 2015; 
Semler et al., 2012).  
 
 
2.2. OI as a spectrum of complex disorders 
All mentioned pathological alterations lead to the development of a complex 
phenotype in OI patients. In addition to expected skeletal features, the spectrum 
of symptoms also include secondary features – extraskeletal characteristics 
(Sissman, 2001). The development of extraskeletal features is associated with 
the presence of type I collagen in many other tissues (eg. ligament, dentin, 
dermis, myofibrils, endomysium, sclera and cornea) (Alharbi, 2015; Gelse et al., 
2003). Symptoms are individual and develop different degrees of severity in 
different patient, leading to diverse phenotypes among affected individuals (Van 
Dijk and Sillence, 2014). Due to the involvement of numerous organ systems in 
disease pathogenesis, OI must be considered as a complex disorder, and 
requires a multidisciplinary approach by health professionals from different 
medical areas (Alharbi, 2015; Dahan-Oliel et al., 2016; Marini et al., 2017). 
 
 
2.2.1. OI skeletal features 
The main symptom of OI is minimal trauma or atraumatic fractures. Fractures 
alter long bones more frequently, as these bones experience greater stress and 
loadings (Lin et al., 2009). OI patients experience a higher incidence of 
fractures compared to the general population; however, the pattern of fracture 
peak distribution among ages is in concordance with that spotted in general 
population (Folkestad et al., 2017). The number of fractures differs depending 
on the severity of the disorder, and ranges from a few to several hundred during 
the lifetime (Sillence, 1981). Despite being referred to as a “brittle bone disease”, 
some OI individuals lack bone fractures; however, they may develop secondary 
OI features (Deodhar and Woolf, 2000). Thus, a diagnosis could be made later 
in life after the transmission of a pathogenic variant to one’s offspring, who 
appears to be more severely affected.  
The highest fracture number happens in toddlers and during adolescence 
(Folkestad et al., 2017). Severe OI cases stand out due to their intrauterine 
fractures. Babies with moderate and severe OI might also experience fractures 
during delivery (Sillence et al., 1979a).  
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Skeletal OI manifestation includes bone deformities (Figure 3). OI patients 
might develop spinal (kyphosis and scoliosis), chest deformities (bell-shaped rib 
cage, pectus excavatum/carinatum), bowing of lower and upper extremities and 
triangular shaping of the head (Marini et al., 2017). Deformities are more 
common in individuals with OI III and IV (Sillence et al., 1979b). Deformities 
of the lower extremities are represented with bowing of the long bones, usually 
anterolateral bowing of the femur and anterior bowing of the tibia. Deformities 
of the lower extremities are found more often because of weight bearing which 
can lead to more frequent fractures (Tadashi Moriwake, 1997). The extreme 
curvature of the bone brings additional stress to the bone tissue and adds an 
additional risk of bone fracture (Jay R. Shapiro et al., 2013). 
Another typical feature of OI is short stature. Short stature correlates with 
disorder severity. Mild OI individuals possess slightly reduced to normal stature, 
whereas individuals with severe OI develop extremely short stature (Sillence et 
al., 1979b). Possible explanations of a height shortage might include spinal 
deformities and aberrations in the cartilage growth plates (Forlino et al., 2011).  
 
 
Figure 3. Skeletal deformities in a patient with severe OI (OI database of Clinic of 
Traumatology and Orthopedics, University of Tartu, Tartu, Estonia). 
 
 
2.2.2. OI extraskeletal features 
One of the typical OI symptoms is blue sclera, which is caused by one of the 
following proposed sources: decreased thickness and increased transparency of 
sclera; altered extracellular matrix composition and thinner collagen fibers; 
decreased light scattering by the sclera; increased viability of the underlying 
choroid (Figure 4a) (Apsey and Bohnsack, 2016). Blue sclera is associated with 
quantitative collagen defect and mild OI; whereas, individuals with moderate 
21 
and severe OI and structural collagen changes as well as pathogenic variants in 
the recessive OI genes usually have grey or white sclera (Das and Bhatnagar, 
2017; Sillence et al., 1979a; Van Dijk and Sillence, 2014). However, correlations 
are still ambiguous, as some of patients with recessive OI pathogenic variants 
develop bluish sclera hue, such as those with pathogenic variants in the 
TMEM38B and SERPINH1 (OMIM 600943) genes (See section 2.4.). Inter-
estingly, sclera hue might also vary in affected members of a single family. It is 
also known, that blue sclera tend to decolorize with age (Marini et al., 2017; 
Van Dijk and Sillence, 2014).  
 
Figure 4. OI extraskeletal manifestations in patients from the OI UT database. (a) Blue 
hue of a sclera (b) Dentinogenesis Imperfecta (DI) (OI database of Clinic of Traumatology 
and Orthopedics, University of Tartu, Tartu, Estonia).  
 
Around 34–78% of OI individuals develop hearing loss of different severity, 
which usually starts during their mid-twenties (Kaija Kuurila and Johansson, 
2000; Kuurila et al., 2002). Hearing loss is progressive and variable among 
patients and OI types. In some cases, it might reach complete deafness. According 
to etiology, hearing loss might be conductive, sensorineural or mixed. Sensori-
neural hearing loss is found mostly in adult patients, whereas conductive hearing 
loss is found in younger patients (Kuurila et al., 2002; Pillion et al., 2011). The 
presence of hearing loss is most common in OI type I and type III, and it 
appears to be rare in type IV (Sillence, 1981). Generally, hearing loss is 
associated with changes in the bones that fixate the footplate of stapes which 
can yield the thinning, atrophy or fractures of stapes and incus (Swinnen et al., 
2012). Also, hearing loss can be induced by skull fractures, seizures or basilar 
invagination (Pillion et al., 2011). Interestingly, there is a lack of correlation 
between hearing loss and OI pathogenic variants. It was hypothesized, that 
additional genes shape the hearing phenotype of OI individuals (Swinnen et al., 
2011, 2009). 
Up to 80% of OI patients might develop DI. DI is characterized with dis-
coloration of enamel, with various shades of dentin (light grey-yellow-dark 
grey), spontaneous dental fractures and enamel loss, modifications of dentin 
matrix, poor mineralization, reduced size of teeth and tooth loss (Figure 4b) 
(Biria et al., 2012; Majorana et al., 2010; Surendra et al., 2013).  
(a)                                               (b)
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Craniofacial manifestations in OI patients include triangular head, Wormian 
bones and malocclusion (Sæves et al., 2009).  
Breathing and lung problems are the main cause of OI deaths (McAllion and 
Paterson, 1996). Pulmonary complications are associated with kyphoscoliosis, 
vertebral collapse, pectus carinatum, short stature, rib fractures and pulmonary 
collagen abnormalities. Pulmonary hypoplasia has been observed in OI patients 
with lethal OI (Shapiro et al., 1989).  
 
 
2.3. OI phenotypic spectrum 
Already from the earliest descriptions of OI cases, clear differences between 
mild and severe forms have been elucidated. Patients, who suffered fractures 
from early childhood and had blue sclera, were classified as an OI congenita. 
Other patients with blue sclera, deafness and bone fragility were put into the 
tarda OI group (Cremin and Beighton, 1978; Zajtchuk and Lindsay, 1975). The 
present classification is not capable to sort discrepant OI cases with highly 




2.3.1. Clinical OI classification 
In 1979, Australian researcher, David Sillence, proposed a classification for OI 
disorder. Sillence highlighted four diverse types: I–IV based on clinical mani-
festations, radiological features and inheritance pattern of OI in observed in 
Australian patients. The number of the type does not resemble the severity of 
the phenotype, but rather the present order, in which patients were described 
(Sillence et al., 1979b). In 2000, Glorieux and Rauch discovered a fifth OI type 
with additional calcification of interosseous membranes and hyperplastic callus 
(HPC) (Glorieux et al., 2000). 
Roman numerals for type designation were implemented into genetic OI 
classification by David Sillence in 1979. In 2014 David Sillence and Fleur van 
Dijk suggested updated OI nomenclature and insisted on five clinical syndromic 
OI forms as the most descriptive and useful for clinical practice. Sillence and 
van Dijk proposed the use of Arabic numerals to differentiate genetic and clinical 
OI nomenclature (OI 1–5). Considering terminology it must be noted, that 
although van Dijk and Sillence proposed a new OI classification (Van Dijk and 
Sillence, 2014) with Arabic numerals, it was not yet accepted by International 
Nomenclature group for Constitutional Disorders ICHG of the Skeleton (INCDS) 
and currently the old classification with Roman numerals is broadly in use.  
OI type I (Mendelian inheritance in man database, MIM 166200) describes 
dominantly inherited, classical, non-deforming OI cases with blue sclera. OI 
type I is the mildest OI form. Incidence is estimated as 1/10,000 births. Patients 
have nearly normal height, hearing loss and mild skeletal deformities (Figure 
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5a). The first fracture occurs usually during the preschool period. The number 
of fractures is minimal. Patients do not develop problems with mobility and are 
able to walk independently (Sillence et al., 1979b). Based on the presence of DI, 
patients are divided into A (with DI) and B (without DI) subtypes. It is supposed, 
that individuals with IA have greater rates of fractures and more severe pheno-
type compared to IB (Paterson et al., 1983). Only 90% of patients suffer from 
fractures (Van Dijk and Sillence, 2014).  
OI type II (MIM 166210) is a perinatal lethal OI. This type is the most severe, 
lethal OI form. Incidence is described as 1/1,000,000. An affected fetus is often 
aborted or dies during the first days of life due to respiratory deficiency. The 
subject suffers numerous intrauterine fractures, severe skeletal deformities, severe 
shortening of the limbs, rhizomelia, beaded ribs, platyspondyly, skin head (soft 
skull). These OI individuals have extremely dark blue eye sclera (Sillence et al., 
1979b). Based on radiological data OI type II was divided into subtype A (short, 
broad long bones, angulation of tibias and continuously beaded ribs); subtype B 
(short, broad, crumpled femurs, angulation of tibias, normal ribs or with in-
complete beading); subtype C (long and thin long bones, multiple fractures and 
thin beaded ribs) (Sillence et al., 1984).  
OI type III (MIM 259420) describes a progressive deforming OI with normal 
sclera. Incidence of OI type III is estimated as 1 to 2 per 60,000 to 100,000. 
Patients develop severe bone fragility and severe skeletal deformities. Patients 
with OI type III have short stature (~1m), triangular head, low set ears and 
temporal, occipital bossing, disproportion of body and limbs (Figure 5c). 
Patients with OI type III might have intrauterine fractures and multiple fractures 
during birth. The number of fractures is extremely high during the patient’s entire 
lifespan. Patients might also develop DI, hearing loss or joint laxity. Sclera hue 
range from pale blue and greyish to white. OI type III phenotype is the most 
severe of the non-lethal OI types. Patients are unable to walk and require wheel-
chairs (Sillence et al., 1979b). 
Figure 5. X-rays of adult OI patients: OI type I (a), OI type IV (b), OI type III (c) 
(Reeder and Orwell, 2006). 
 
(a)                                       (b)                                        (c)
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OI type IV (MIM 166220) is a common variable OI with normal sclera. Patients 
have moderate OI phenotype. This group includes various OI cases. Stature is 
higher compared to OI type III, but shorter than patients with OI type I. Skeletal 
deformities are moderate, affecting mostly lower limbs. Patients require 
assistance for walking. The number of fractures is significantly higher compared 
to OI type I (Figure 5b) (Sillence et al., 1979b). Intrafamilial severity is highly 
variable. In some families there a majority of family members present mild OI 
with a few having moderately severe OI (Holcomb, 1931; Seedorf, 1949). 
OI type V (MIM 610967) is underlined by calcification abnormalities, like 
interosseous membrane calcification in the forearms and legs (Figure 6C–E). 
This pathologic ossification restricts pronation and supination of the affected 
limb. All patients were reported to develop dislocation of the radial head in the 
forearm. Sclera were reported as white, no DI and hearing loss were previously 
described in these patients. OI type V individuals have typical histomorpho-
metry with a coarse mesh-like pattern of lamellation (Figure 6A, B) (Rauch et 
al., 2013). Patients with OI type V might develop HPC of different severity 
(Figure 6F). HPC is a massive benign callus with swelling and pain at the site of 
fracture or surgery, which has the tendency to increase and disappear later in 
life (Cheung et al., 2007; Glorieux et al., 2000; Rauch et al., 2013). Recent 
descriptions of OI type V cases prove the high variability of OI type V pheno-
types (Balasubramanian et al., 2013; Fitzgerald et al., 2013; Guillén-Navarro et 
al., 2014; Rauch et al., 2013; Jay R Shapiro et al., 2013). 
Figure 6. Histological and radiological findings in patients with OI type V. (A) Lamellar 
pattern of the Haversian system from a normal subject. (B) Mesh-like lamellar pattern in 
OI type V. (C–E) Ossification of the interosseous membranes. (F) Hyperplastic callus. 
Adapted from (Cho and Moffatt, 2014). 
 
 
2.4. Genetic OI nomenclature and genetic heterogeneity  
Research into OI genetics has caused the development of a new approach to OI 
classification, which is based on genetic-functional defects. Genetic OI classi-
fication differentiates 19 OI types, where every type is associated with a separate 
gene (Table 2) (Marini et al., 2017). Sillence types I–IV correspond with addi-




Up to 85–90% of OI cases are caused by autosomal dominant (AD) patho-
genic variants in the COL1A1 and COL1A2 genes, which encode α1 and α2 
chains of type I collagen (Marini et al., 2007). The remaining 10–15% of OI cases 
are caused by 19 non-collagen OI genes. Most of them are AR. These genes 
encode proteins involved in post-translational modification (CRTAP, P3H1, 
PPIB), processing, transport and cross-linking (FKBP10, BMP1 (Online 
Mendelian Inheritance in Man (OMIM) database 112264)), SERPINH1, PLOD2 
(OMIM 601865), SEC24D) of the type I collagen; bone tissue mineralization 
(SERPINF1 (OMIM 172860), IFIMTM5 (OMIM 614757); AD) osteoblast 
differentiation and functioning (WNT1, TMEM38B, SPARC (OMIM 182120), 
SP7 (OMIM 606633), CREB3L1 (OMIM 616215), MBTPS2 (OMIM 300294); 
X-linked (XR)) and osteoclast function (PLS3;XR) (Van Dijk and Sillence, 
2014b; Marini et al., 2017). Lately, a connection between the TENT5A or 
FAM46A, (OMIM 611357) and NBAS (OMIM 608025) genes to OI has been 
confirmed (Figure 7) (Balasubramanian et al., 2017; Doyard et al., 2018). Some 
OI cases lack a genetic diagnosis implying the existence of still unidentified OI 
genes (Bardai et al., 2016).  
Although OI might be caused by pathogenic variants in numerous genes, OI 
phenotypes overlap and resemble the classical clinical OI types I–V (Table 2) 
(Van Dijk and Sillence, 2014).  
 
 
Figure 7. Idiogram of OI genes showing genetic heterogeneity. The OI idiogram 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.1. Autosomal dominant OI 
 A majority of OI individuals are affected by an autosomal dominant form of OI 
(Sillence et al., 1979b). These patients are carriers of only one mutated allele on 
the somatic chromosomes, which is enough to develop OI symptoms. Dominant 
pathogenic variants might be inherited from patients or arise de novo in 35–60% 
of cases (Steiner et al., 1993). In the case of familial OI, the probability of 
transmission of a pathogenic variant to next generation is 50%. OI patients with 
types I and IV show predominantly an AD pattern of inheritance. Some of the 
families with OI type III also show AD inheritance (Tsipouras et al., 1984; van 
Dijk et al., 2012). A majority of the AD pathogenic variants alter COL1A1 and 
COL1A2 genes and cause classical OI types (Steiner et al., 1993). All reported 
OI type V cases were caused by the same AD pathogenic variant in the IFITM5 
gene (Semler et al., 2012). One more non-collagen OI gene with AD pattern is a 
WNT1. Pathogenic variants in this gene are associated with different severity of 
bone fragility. AD pathogenic variants cause mild phenotype or early-onset 
osteoporosis (OP), whereas AR pathogenic variants are responsible for severe 
OI (Keupp et al., 2013).  
 
 
2.4.1.1. Collagen I – related OI 
The importance of collagen type I is underlined by the high conservation of this 
protein among vertebral organisms (Bonod-Bidaud and Ruggiero, 2013; Gelse 
et al., 2003; Stover and Verrelli, 2011). Naturally collagen type I lacks variation 
especially in the N- and C-domains, as these termini are involved with collagen 
assembly, transport and signaling (Stover and Verrelli, 2011). More than 1500 
different pathogenic variants were described in the COL1A1/2 genes in the 
database of OI variants (Dalgleish, 1997).  
Collagen-related OI is characterized with classical Sillence phenotypes and 
typical OI features like: atraumatic fractures, blue sclera, DI, hearing loss, skeletal 
deformities, easy bruising and joint hypermobility (Sillence et al., 1979b; Van 
Dijk and Sillence, 2014). Pathogenic variants in the collagen I cause a highly 
variable spectrum of bone fragility (Bonod-Bidaud and Ruggiero, 2013; Lisse et 
al., 2008; Steiner et al., 1993). Pathogenic variants of the COL1A1/2 genes can 
cause any range of OI types I–IV, including a lethal OI type II, see Table 2 
(Marini et al., 2007). Parental mosaicism may be found in 3–5% of OI cases. 
Parents with somatic mosaicism are usually mildly affected, whereas parents 
with somatic mosaicism may reveal mild clinical symptoms of OI. In cases of 
parental mosaicism the offspring may develop recurrent AD OI (Chen et al., 
2013; Frederiksen et al., 2016). In addition to OI, pathogenic variants in the 
COL1A1 and COL1A2 can lead to Caffey disease, Ehlers-Danlos syndrome 




2.4.1.1.1. COL1A1: characteristics and relation to OI 
The COL1A1 gene is located on the 17q21.33, reverse strand (Figure 7). The gene 
codes for a collagen type I α1 chain (Figure 1). COL1A1 mRNA is mono-
cistronic (Lazarides and Lukens, 1971). Collagen type I from bone, skin and 
tendon tissue differ in pattern of hydroxylation of Pro and Lys residues, cross-
linking formation and glycosylation (Boedtker et al., 1983). The characteristic 
feature of the collagen genes is numerous small exons. The COL1A1 consists of 
a 51 coding exon. Up to 90% of OI, patients harbor pathogenic variants in the 
COL1A1 gene (Steiner et al., 1993). According to Körkkö, 1/5 of the COL1A1 
pathogenic variants are identical in unrelated OI individuals. 80% of these 
recurrent OI pathogenic variants are located in the CpG islands (Körkkö et al., 
1998). OI pathogenic variants have been identified in all exons. Severity of the 
phenotype depends on the location and type of the pathogenic substituting aa 
residue (Marini et al., 2007).  
 
2.4.1.1.2. COL1A2: characteristics and relation to OI 
The COL1A2 gene is located on the 7q21.3, forward strand (Figure 7). The gene 
codes for collagen type I α2 chain (Figure 1). The gene is composed of 52 exons. 
Compared to COL1A1, fewer individuals harbor COL1A2 pathogenic variants, 
only up to 30% (Körkkö et al., 1998; Steiner et al., 1993). Carriers of the COL1A2 
pathogenic variants generally have less severe phenotype compared to carriers 
of the pathogenic variants in the COL1A1 gene. This is explained by a fewer 
number of α2 chains in the collagen triple helix, so that only 25% will have 
normal α2 chain, compared to 75% in the case of an abnormal α1 chain (Marini 
et al., 2007; Jay R Shapiro et al., 2013). Lethal pathogenic variants may appear 
in both genes, with a predominance in the COL1A2 (Marini et al., 2007). The 
number of the LoF pathogenic variants in the COL1A2 gene is reduced, as they 
are supposed to cause an asymptomatic form of the disease or the mildest 
symptoms (i.e. early onset OP) and are not captured by clinical detection (Pope 
et al., 1985). There were no previous descriptions of the complete COL1A2 
deletions (Jay R Shapiro et al., 2013).  
 
 
2.4.1.2. Association of the IFITM5 gene with OI 
OI type V individuals harbor a heterozygous pathogenic variant in the 5’ un-
translated region (UTR) of the IFITM5 gene, c.–14C>T (Cho et al., 2012; Semler 
et al., 2012). The gene is located on the 11p15.5, reverse strand and consists of 
two exons (Figure 7). The physiological function as well as the pathogenic 
mechanism of the 5’UTR pathogenic variant of the IFITM5 gene are not yet 
well understood. The IFITM5 gene product – BRIL protein, is believed to be in-
volved with the development and mineralization of the bone tissue. Interestingly, 
a co-expression of ifitm5 with col1a1 and other OI-related genes was observed 
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in a murine model of OI (Farber et al., 2014). It was shown that the c.–14C>T 
pathogenic variant causes an emergence of a new upstream start codon and 
facilitates the inclusion of five redundant amino acids to the N-termini of the 
protein – Methionine, Alanine, Leucine, Glutamic acid and Proline (MALEP) 
(Hanagata, 2016; Lazarus et al., 2014). The consequence of the pathogenic 
variant on protein function remains debated. One hypothesis suggests that there 
is evidence of a gain-of-function effect of the pathogenic variant. However, 
others point towards neomorphic nature of the c.–14C>T pathogenic variant in 
the IFITM5, proving that mutated MALEP-IFITM5 protein gains a new 
molecular function (Lietman et al., 2015). The first evidence of association of 
OI type V with IFITM5 was published in 2012. Incidence of patients who 
harbor the c.–14C>T IFITM5 pathogenic variant remains rare. Moreover some 
of the pathogenic variant carriers do not express typical symptoms of the OI 
type V phenotype and lack a diagnosis (Figure 6) (Cho et al., 2012; Grover et 
al., 2013; Semler et al., 2012). In addition, a c.119C>T, p.(Ser40Leu) hetero-
zygous pathogenic variant in the IFITM5 gene has been described to cause a 
typical OI type III with progressive deformities, grey sclera, limb shortening 
and lacks the typical symptoms of OI type V (Guillén-Navarro et al., 2014). A 
pathogenic variant in the same position p.(Ser40Trp) caused multiple prenatal 
fractures in an affected individual. However, the patient had normal BMD after 
birth and only a few fractures appeared during adolescence, after a significant 
trauma (Lim et al., 2019). Thus, the phenotypical range of IFITM5-related OI 
 
 
2.4.2. Autosomal recessive OI 
Only 10% of OI cases have AR inheritance. In AR cases, an affected person must 
inherit two copies of a mutated allele (biallelic) in order to develop a disease 
phenotype.  
These pathogenic variants may be homozygous (at the same position) or 
compound heterozygous (at different positions). AR is observed in collagen 
type I genes, as well as non-collagen OI genes, which are also called AR OI 
genes, due to the predominance of a recessive inheritance pattern among them 
(Table 2) (Marini et al., 2017; Van Dijk and Sillence, 2014).  
The inheritance pattern of the collagen-related OI is mostly AD; however, 
some AR pathogenic variants were also reported. Individuals, harboring homo-
zygous and compound heterozygous variants in the collagen I genes develop 
much more severe phenotypes compared to carriers of the same heterozygous 
variants (Ackermann and Levine, 2017; De Paepe et al., 1997; Pope et al., 1985). 
A few cases from consanguineous families with heterozygous parents with mild 
OI resulted in homozygous, severely affected children (De Paepe et al., 1997; 
Pope et al., 1985). 
Non-collagen OI genes are mostly AR. The current number of known AR non-
collagen OI genes is 16. Mutations in the AR OI genes cause the development 
might be greater than estimated. 
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of severe OI phenotypes OI types II and III, which are usually indistinguishable 
from collagen-related OI (Table 2) (Marini et al., 2017). Pathogenic variants of 
the AR OI genes lack LoF variants, which lead to null allele and a significant 
decrease in protein synthesis or the total absence of a gene product (Van Dijk 
and Sillence, 2014). 
 
 
2.4.3. Pathogenic variant types 
Pathogenic variants are important factors of disease progression, altering gene 
expression, size, structure and genetic interactions. Their effect on organism 
fitness can be lethal, deleterious, neutral (i.e. benign) or beneficial. Pathogenic 
variants can be classified as insertions-deletions (indels), SNVs and chromosomal 
aberrations (Nishant et al., 2009). OI is usually caused by indels and SNVs. 
However, cases of chromosomal aberrations that adjust COL1A1/2 loci have 
also been described (Knisely et al., 1988). Pathogenic variants can be located in 
introns (non-coding regions) or exons (coding regions). As a rare disorder, OI is 
caused predominantly by pathogenic variants in the exons, splice sites, 3’ or 5’ 
UTR. Collagen I pathogenic variants may be classified according to the type of 
defect – quantitative (LoF, i.e. haploinsufficiency) or qualitative (missense, i.e. 
dominant negative (DN)) pathogenic variants (Marini et al., 2007). 
According to the standards and guidelines of the American College of Medical 
Genetics and Genomics (ACMG) and the Association of Medical Pathology, all 
genetic variants which cause Mendelian disorders are classified into variants 
using specific, standard terminology – “pathogenic,” “likely pathogenic,” “un-
certain significance,” “likely benign,” and “benign”. Five categories are based 
on criteria, which summarize types of variant evidence, such as population, 
computational, functional and segregation data (Richards et al., 2015). 
 
 
2.4.3.1. Dominant negative pathogenic variants:  
missense pathogenic variants 
When COL1A1/2 genes are altered, DN pathogenic variants disrupt triple helix of 
the collagen I polypeptides. As a result propeptide is overprocessed with enzymes 
during post-translational modification and an abnormal collagen I is produced, 
which is rapidly degraded (dominant-negative effect) (Van Dijk and Sillence, 
2014). Being a structural defect, DN pathogenic variants correspond with colla-
gen type I qualitative abnormalities. DN pathogenic variants cause the synthesis 
of structurally abnormal collagen, which may cause ER stress and apoptosis of 
osteoblasts. The structural defects have a more severe effect on ECM than on 
ECM insufficiency (Forlino and Marini, 2000). DN pathogenic variants are 
therefore more deleterious than LoF pathogenic variants (Ben Amor et al., 
2011; Marini et al., 2007; Mendoza-Londono et al., 2015; Jay R. Shapiro et al., 
2013). 
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DN pathogenic variants in the collagen I triple helical domain result in a range 
of phenotypes, from lethal to moderately severe OI. Out of the missense patho-
genic variants, the most common forms with clinical significance are Gly sub-
stitutions (Kuivaniemi et al., 1997; Prockop and Kivirikko, 1984). Almost 80% 
of Gly is substituted with Ser, Cys and Arg. Around 9% of Gly substitution 
leads to OI type I (Marini et al., 2007). However, in a Swedish population-based 
study 32% of mild OI cases were caused by qualitative pathogenic variants 
(Lindahl et al., 2015). 
DN pathogenic variants appear more frequently as compared to LoF (i.e. 
frameshift and splice site) pathogenic variants in sporadic genetic diseases (de 
Ligt et al., 2013; Veltman and Brunner, 2012). The missense substitutions were 
claimed to be the most common among patients of European and North Ameri-
can origin (Van Dijk and Sillence, 2014). 
 
 
2.4.3.2. Haploinsufficiency pathogenic variants:  
indels, splice site, frameshift pathogenic variants 
Haploinsufficiency effect is caused by LoF pathogenic variants, which are re-
presented with indels, splice site and frameshift variants, leading to instability 
of the mRNA. LoF pathogenic variants in type I collagen genes lead to a reduced 
production of collagen, but the structure of molecules is not altered. Thus, LoF 
pathogenic variants in COL1A1/2 genes correspond to haploinsufficiency and a 
collagen type I quantitative defect.  
Nonsense pathogenic variants lead to the PTC and NMD of an affected chain. 
Not all nonsense pathogenic variants result in OI type I. Sometimes PTC of a 
nonsense pathogenic variant results in a moderately severe or severe phenotype. 
This underlines the issue that in case of nonsense pathogenic variants, pheno-
type cannot be explained with null allele directly (Kocher and Shapiro, 1998). 
Frameshifts are more common for the COL1A1 gene, compared to COL1A2. 
Frameshifts appear in all exons and usually result in PTC, NMD and mild OI. 
However, frameshifts in exon 50 and 51 will not result in NMD and truncated 
protein will cause severe DN effects (Hartikka et al., 2004; Pollitt et al., 2006). 
Splice site pathogenic variants cause intron or exon cryptic splice site acti-
vation, exon skipping and intronic retention. Donor (5’) and acceptor (3’) splice 
site pathogenic variants in the COL1A1/2 genes appear with the same fre-
quency. It would be expected, that exon skipping caused by splice site patho-
genic variants might lead to a DN effect, as translation protein includes internal 
amino acid deletion. In contrast, 80% of splice site pathogenic variants result in 
mild OI. This is expected from the production of null-alleles, rather than trun-
cated proteins (Kocher and Shapiro, 1998). Phenotype predictions might be 
dependent on additional variants, which modify the splicing process. These 
variants may include: cis-factors, single nucleotide polymorphisms (SNPs), 
which directly influence splicing; SNPs in regulatory regions, which alter gene 
expression; trans-factors, which alter tissue-specific splicing (Garcia-Giralt et 
al., 2002; Grant et al., 1996). 
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About 1–2% of individuals with COL1A1/2 pathogenic variants have exon/ 
whole gene deletions. Deletions of the whole gene or exons also result in 
haploinsufficiency and mild OI type I phenotype (van Dijk et al., 2010). 
 
 
2.4.3.3. De novo and familial pathogenic variants 
De novo pathogenic variants are spontaneously appearing variants. De novo 
pathogenic variants are also referred to as “sporadic” pathogenic variants. De 
novo pathogenic variants differ by having a greater effect on phenotype and are 
more deleterious compared to inherited (i.e. familial) pathogenic variants 
(Acuna-Hidalgo et al., 2016; Veltman and Brunner, 2012). Due to their sporadic 
nature, the amount of the de novo pathogenic variants remain frequent in the 
population. There are no differences in the prevalence of de novo pathogenic 
variants among different ethnic groups and populations (Acuna-Hidalgo et al., 
2016). These variants might cause congenital malformations, rare disorders and 
sporadic syndromes in previously unaffected families (Veltman and Brunner, 
2012). Interest towards de novo pathogenic variants has increased alongside the 
availability of NGS techniques. Understanding the contribution and importance 
of de novo pathogenic variants in rare and common disorders is growing. De 
novo pathogenic variants are the main source of neurodegenerative and develop-
mental disorders (Acuna-Hidalgo et al., 2016).  
OI is considered to be a mainly hereditary disorder with a family history. 
However, OI pathogenic variant etiology might not only be inherited but in 35–
60% of cases de novo (Steiner et al., 1993). Less attention is paid to the input of 
de novo pathogenic variants in OI pathology. Investigations of de novo patho-
genic variants in the context of musculoskeletal disorders is essential for under-




2.5. Genotype-phenotype associations in OI 
Understanding genotype-phenotype correlations is important for the evaluation 
of disease progression and prediction of risks as well as diagnosis, including the 
reduction of genetic diagnosis costs, family planning, management and treatment 
strategies. However, it is difficult to elucidate OI genotype-phenotype asso-
ciations, as high variability of phenotype expressivity exists. Researchers are still 
trying to compose OI genotype-phenotype correlations (Jay R Shapiro et al., 
2013). 
Phenotype severity depends on the affected gene. Interestingly, due to com-
mon pathological mechanisms, the phenotypes of patients with different mutated 
OI genes might mimic each other or overlap. Prolyl 3-hydroxylase 1-Cartilage-
associated protein-Peptidyl-prolyl cis-trans isomerase B protein complex (P3H1-
CRTAP-PPIaseB) complex is a product of P3H1, CRTAP and PPIB genes. 
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Pathogenic variants in these genes might cause similar phenotypes: lethal or 
extremely severe OI (Table 2, Figure 8) (Baldridge et al., 2008; Morello et al., 
2006; van Dijk et al., 2009)  
However, in some cases distinctive features are developed depending on the 
altered gene. For example: ossification of interosseous membranes and HPC in 
patients with IFITM5 gene pathogenic variants; optic atrophy and loss of color 
vision, growth retardation, facial dysmorphism in individuals with NBAS gene 
pathogenic variants; contractures in carriers of the PLOD2 and FKBP10 gene 
pathogenic variants (Table 2) (Balasubramanian et al., 2017; Hanagata, 2016; 
Y. Liu et al., 2017; Shaheen et al., 2010).  
According to a study of 50 Indian OI individuals, phenotype severity ranged 
as follows: IFITM5 = LEPRE1 > WNT1 > SERPINF1 > COL1A1 (qualitative) > 
BMP1 > FKBP10 > COL1A2 (qualitative) > COL1A1 (quantitative) > COL1A2 
(quantitative) (Mrosk et al., 2018). This presented range might be subjective, 
due to the limited number of patients and high variability of clinical manifes-
tations between carriers of the pathogenic variants in the same gene. In addition 
to the affected gene, phenotype is strongly influenced by the type of pathogenic 
variant and position (Jay R Shapiro et al., 2013). For example, alterations in the 
IFITM5 and SP7 may cause both severe and moderate phenotype (Figure 8) 
(Marini et al., 2017).  
 
 
Figure 8. General representation of OI phenotype severity according to the affected OI 
gene. 
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There is an advanced understanding of genotype-phenotype correlations in 
collagen-related. According to previous studies, phenotype in collagen I related 
OI is influenced by pathogenic variant type and position, so genotype-pheno-
type associations exist to some extent (Marini et al., 2017, 2007). It was shown, 
that generally quantitative defects are associated with milder OI, whereas 
qualitative collagen defects are associated with moderate and severe OI (Sillence 
et al., 1979a). Modern approaches to OI are variant-centric; however, OI is a 
complex disorder and the identification of modifier factors, both genetic and 
epigenetic ones, is essential for a full understanding of the disease. 
Generally, individuals with COL1A2 pathogenic variants have more severe 
phenotypes compared to patients with COL1A1 pathogenic variants (Maioli et 
al., 2019; Marini et al., 2007; Mrosk et al., 2018). In addition, there is a strong 
association between phenotype and the position of the variant. Individuals 
harboring N-propeptide pathogenic variants develop EDS/OI overlap pheno-
type, whereas pathogenic variants in the C-propeptide are associated with a high 
bone mass OI. Correlations between blue sclera, DI and fracture number are 
believed to be identified to some degree. N-terminal helical pathogenic variants 
are associated with blue sclera, and C-terminal helical pathogenic variants are 
associated with DI (Rauch et al., 2010). Dental abnormalities are associated 
with qualitative defect in the collagen I. Th severity of the DI depends on the 
location of the pathogenic variant (Andersson et al., 2017). However, in a recent 
study of 364 Italian OI patients, a correlation between pathogenic variant 
location and DI presence was absent (Maioli et al., 2019). Interestingly, Maioli 
et al. also confirmed a lack of correlation between lethal OI and these “lethal 
clusters”, as proposed by Marini et al. (Maioli et al., 2019; Marini et al., 2007). 
Patients with COL1A1 pathogenic variants have a greater prevalence of blue 
sclera compared to carriers of the COL1A2 pathogenic variants. Carriers of the 
COL1A2 pathogenic variants, however, are shorter compared to those with 
COL1A1 pathogenic variants. The association between genotype and hearing is 
still unknown, as there no correlation has been found between gene, pathogenic 
variant type or position and presence of hearing loss. Hearing loss is suspected 
to be a multifactorial trait and depends on complex genetic factors (Hartikka et 
al., 2004). However, in a recent study of 668 Chinese OI patients, a correlation 
between the absence of hearing loss and Gly substitutions in the α1 chain  
N-terminal end was observed (Li et al., 2019). 
 
 
2.6. Inter- and intrafamilial diversity 
Incomplete penetrance and clinical variability has been described previously for 
many AD disorders (Castori, 2012; Cooper et al., 2013; McGettrick et al., 2000). 
Clinical variability causes mis- and underdiagnosis in cases of asymptomatic 
patients, especially for mildly affected families, who still transmit disease caus-
ative pathogenic variants to the next generation (Cooper et al., 2013; Deodhar 
and Woolf, 2000). 
36 
With enrichment of the OI variant database, OI genotype-phenotype correla-
tions have become less clear. Variability of phenotypic variants under a single 
pathogenic variant have been elucidated. The existing variability of OI pheno-
types between related and unrelated individuals has been observed for a long 
time (Daley et al., 2010; Deodhar and Woolf, 2000; Moraes et al., 2012; 
Rogozhina et al., 2016; Jay R Shapiro et al., 2013; Swinnen et al., 2011). The 
OI variant database (https://oi.gene.le.ac.uk) has reported unrelated patients, 
who harbor the same pathogenic variant; however, they suffer from different 
severities of the disease. One such case of a c.757C>T (p.Arg253*) nonsense 
pathogenic variant in the COL1A1 gene was reported 11 times. Patients 
developed following the OI types: six OI type I, four OI type IV, one OI type III 
(Dalgleish, 1998; Lindahl et al., 2015; Mauri et al., 2016; Ries-Levavi et al., 
2004; Jay R. Shapiro et al., 2013; Venturi et al., 2006). One of the most 
outstanding examples of familial OI diversity is from a study of 64 individuals 
from 22 Old Order Amish sibships, all harboring a single founder AD patho-
genic variant c.2237G>T, p.(Gly610Cys) in the COL1A2 gene. The phenotype 
spectrum between carriers of the pathogenic variant ranged from mild to 
moderate in the community (Daley et al., 2010). Affected patients develop 
phenotypes with different severity of bone fragility, fracture numbers, severity 
of skeletal deformities, hearing loss, DI, sclera hue and joint hypermobility 
(Dalgleish, 1997; Pillion et al., 2011; Swinnen et al., 2011). High intrafamilial 
variability is also exposed by hearing loss characteristics, underling the presence 
of additional genetic factors in a predisposition for hearing loss in OI individuals 
(Swinnen et al., 2011). Variability of phenotypes cannot be explained by dif-
ferences in treatment, as asymptomatic, untreated parents might have more 
severely affected children, who develop the need of pharmacological treatment 
and orthopedic interventions. 
In some cases, intrafamilial diversity is explained with mosaic parents, who 
are mildly affected or asymptomatic. Also in cases of WNT1 and CREB3L1 
pathogenic variants, heterozygous family members might be mildly affected 
when compared to severely affected homozygous individuals (Laine et al., 2013; 
Symoens et al., 2013). Variable expressivity, including intrafamilial diversity of 
phenotype, was spotted in families with OI type V. Some of these patients are 
able to ambulate independently, whereas others use walking aids or wheelchairs 
(Jay R Shapiro et al., 2013).  
Families from the OI database of the Clinic of Traumatology and Ortho-
pedics (University of Tartu, Estonia) also expose cases of inter- and intra-
familial variability. Patients carrying the same type of collagen I defect (i.e. DN 
or LoF COL1A1/2 pathogenic variants) or even carriers of the same pathogenic 
variant developed different OI symptoms. Intrafamilial variability was observed 
in the differences of OI phenotype between affected members of the single 
family. Phenotype severity increased, or oppositely decreased, throughout 
generations. Also, phenotypes might differ between affected siblings from the 
same generation. In some families, no differences in phenotype severity were 
registered and the clinical picture of all affected members was identic.  
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2.7. Summary of the literature review 
OI is a spectrum of heterogeneous complex of bone fragility disorders. OI is a 
rare disease, which affects 1 in 10,000 to 20,000 people. As a disorder of the 
connective tissue, the majority of OI cases are connected to abnormalities in the 
collagen type I. OI patients may develop skeletal (fractures, deformities, joint 
laxity) and extraskeletal (hearing loss, blue sclera, DI, cardio-pulmonary compli-
cations) symptoms. Patients are challenged with diagnostic issues, a need for 
complex treatment approaches, an absence of a cure and a poor quality of life. 
OI unifies different disorders of bone fragility, which range from mild to 
severe and even lethal cases. The disorder is classified into five clinical types 
(I – mild, II – lethal, III – severe, IV – moderate, V – OI with unusual mineraliza-
tion pattern), and 19 different genetic OI types, according to an affected gene. 
The pathogenic variants in the genes, coding for collagen type I (COL1A1/2 
genes) are mainly dominant and might cause OI types I–IV. Collagen type I 
pathogenic variants may cause quantitative (LoF) or structural collagen defect 
(DN). Although phenotype-genotype correlations exist to a certain extent, there 
are many concerns regarding phenotype prediction based on a genotype, as 
symptoms develop individually.  
The OI causing pathogenic variants may occur as de novo or can be hereditary. 
However, it is generally known that the more severe the phenotype the higher is 
the proportion of de novo cases, characterization of the de novo collagen-related 
OI was never addressed before. 
OI type V is a rare OI type, which compromises 2–5% from general OI popu-
lation. OI V arises due to 5’UTR c.–14C>T pathogenic variant in the IFITM5 
gene. Type V patients differ phenotypically with HPC, interosseous membrane 
calcifications and dislocation of the radial head. Type V patients lack hearing 
loss, DI and blue sclera. It is known, that clinical manifestations may vary 
between affected individuals, raising the value of phenotype descriptions for all 
patients with a confirmed genetic diagnosis of OI type V. 
OI phenotype expressivity differs between carriers of the same pathogenic 
variant. OI inter- and intrafamilial diversity has been previously underlined, 
mainly in case reports; however, there is an urgent need for a systematic 
analysis of collagen-related OI phenotypical variability in terms of genotype. 
The current studies might benefit diagnosis and future therapeutics.  
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3. AIMS OF THE STUDY 
The current thesis represents a large cohort studies of Osteogenesis Imperfecta 
patients with the overall objective to characterize a common profile of patho-
genic variants and to evaluate genotype-phenotype correlations with inter- and 
intrafamilial diversity in OI families.  
 
The specific aims were: 
1. To characterize the COL1A1 and COL1A2 spectrum of pathogenic variants 
in a population of Estonian OI patients (Paper I); 
2. To describe the clinical characteristics and molecularly specify COL1A1- 
and COL1A2-related OI in a cohort of Ukrainian OI families (Paper II); 
3. To investigate de novo and inherited COL1A1 and COL1A2 pathogenic 
variants in terms of genotype characteristics and phenotype severity (Paper 
III); 
4. To screen Estonian, Ukrainian and Vietnamese OI patients for the presence 
of an OI type V causative pathogenic variant (Paper IV); 
5. To analyze correlations between inter- and intrafamilial variability and the 





4. MATERIALS AND METHODS 
4.1. Study cohort 
The study cohort was formed using patients from the Osteogenesis Imperfecta 
database of the Clinic of Traumatology and Orthopedics, University of Tartu, 
Estonia (UT OI database). The UT OI database consists of 238 OI families from 
Estonia (EE), Ukraine (UA) and Vietnam (VN). The database includes OI 
affected individuals and their healthy relatives. The total number of affected 
individuals in the database is 337. 
 
 
4.1.1. Paper I 
COL1A1/2 sequencing analysis was performed on 30 unrelated Estonian OI 
patients. Estonian OI families come from a register-based cohort of OI patients 
in Estonia of the Clinic of Traumatology and Orthopedics, Tartu University 
Hospital (Tartu, Estonia). The Estonian OI system was established in 1995, 
when it was agreed that all patients diagnosed with OI or suspected to have OI 
would be referred to Clinic of Traumatology and Orthopedics, Tartu University 
Hospital. The number of OI individuals in the Estonian database is 128. We 
assume that we have contacted almost all known OI families in Estonia.  
 
 
4.1.2. Paper II 
COL1A1/2 sequencing analysis was performed on 94 unrelated Ukrainian OI 
patients. Phenotype description was performed on 143 Ukrainian OI patients 
from 94 families. Ukrainian families were enrolled into the UT OI database via 
a collaboration with the Ukrainian Association of Crystal People and the 
Kharkiv Sytenko Institute of Spine and Joint Pathology (Ukraine). We have 
performed research trips to the West (Chernivci), East (Kharkiv) and Central 
(Kyiv) regions of the country to meet the patients. In May 2016 and September 
2017, Ukrainian OI patients and their relatives (from all regions of Ukraine) 
attended interviews and clinical examination with researchers from the Uni-
versity of Tartu (Estonia) in cooperation with Ukrainian medical staff. Although 
the recruitment of the patients was population-based and there is no single 
register of OI patients in Ukraine, we have included all available patients from 
the Ukrainian Association of Crystal People and Ukrainian hospitals, of which 
the local community was made aware. Patients with other skeletal disorders 
were excluded from the study during screening (five families). A total number 
of 143 OI patients (66 males and 77 females; aged from 2 months to 65 years) 
from 94 unrelated families were included in the study.  
 
 
4.1.3. Paper III 
Analysis of de novo and inherited OI cases was performed in 146 unrelated 
subjects harboring COL1A1/2 pathogenic variants from Estonian, Vietnamese and 
Ukrainian cohorts of the UT OI database. 
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4.1.4. Paper IV 
Screening for the c.–14C>T pathogenic variants in the 5’UTR region of the 
IFITM5 gene was performed in 90 unrelated OI patients negative for COL1A1/2 
pathogenic variants. Patients originated from Estonian (27), Ukrainian (62) and 
Vietnamese (57) OI cohorts of the UT OI database.  
 
 
4.1.5. Paper V 
An analysis of interfamilial diversity was performed in 81 families with 
COL1A1/2 pathogenic variants, whose pathogenic variant and caused OI type 
were reported at least twice in the UT OI database or Dalgleish’s OI variant data-
base (http://www.le.ac.uk/ge/collagen/) (Dalgleish 1998). Intrafamilial diversity 
was explored in 64 families with collagen I-related OI, which was reported in at 
least two generations of the family. In addition, in four families OI was 
identified in a few siblings from the same generation without a previous OI 
history, whose parents were tested and did not carry the variant (Figure 10). 
 
 
Figure 10. Pedigree trees of families with a few affected individuals in the same 




All laboratory procedures and data analysis were performed at the University of 
Tartu, Estonia. In the current thesis Rome numerals (I–V) stand for clinical OI 
classification. The term “pathogenic variant” is used in the thesis in concordance 
with current guidelines of the ACMG, whereas the first publication contains the 
term “mutation” as a synonym (Richards et al., 2015).  
 
 
4.2.1. Data and sample collection 
Genealogical data was obtained in spoken word from subjects during oral 
interviews and included family consanguinity; OI family history; parental ages; 
health status; history of miscarriages. Pedigree trees were constructed using the 
“Kinship2” package in the R statistical program v3.3.2. (R team, Austria). 
To evaluate OI clinical features, patients underwent clinical and physical 
examinations. OI cases were classified as OI types I–V, according to the 
observed clinical manifestations. Clinical data was recorded from available 
medical records. Phenotype description was assessed by observation. Skeletal 
fractures and deformations (severity, location) and extra-skeletal OI features 
(sclera color, DI) were noted. All sclera shades on the blue-gray scale were 
defined as “blue”. Phenotypic data was obtained from the available medical docu-
mentation or from the patients or their relatives, including birth data (weight, 
height, intrauterine and birth fractures, preterm pregnancy); anthropometric data 
(weight and height); fracture history (time and location of the first fracture, total 
number of fractures, number of fractures per year); patient physical mobility; 
occurrence of hearing loss; joint laxity. The OI type and phenotype registration 
was conducted by a single medical professional to avoid bias.  
Blood samples were obtained from the affected family members and their 
close healthy relatives. An ethylenediaminetetraacetic acid (EDTA)-preserved 
tubes were used for the entire blood sample collection and genomic DNA 
(gDNA) purification was performed using the Gentra Puregene Blood Kit 
(Quiagen, Germany) in accordance with the manufacturer’s protocol. DNA 
samples were stored at −80°C until their analysis. 
 
 
4.2.2. Sequencing analysis 
4.2.2.1. Sequencing analysis of the COL1A1/2 genes (Paper I, II) 
COL1A1/2 gene sequencing analysis was performed on the youngest affected 
individual from every OI kindred of 30 Estonian and 94 Ukrainian OI families. 
25 polymerase chain reaction (PCR) primer pairs were used to amplify the 
COL1A1 gene (51 exons) in the DNA samples of affected Estonian and 
Ukrainian OI patients. The COL1A2 gene (52 exons) was amplified with 36 
PCR primer pairs. Primers were designed to cover all exons, 5’and 3’UTR 
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regions. The list of COL1A1 and COL1A2 primers is provided in Appendix A. 
The PCR reaction was performed in 20 μl final volume, with 4 μl of 5x HOT 
FIREPol® Blend Master Mix Ready to Load with 7.5 mM MgCl2) (Solis 
BioDyne, Estonia), 1 μl of each forward and reverse primer (5 pmol), 1 μl of 
gDNA (50 ng). PCR reaction was performed using a Thermal Cycler (Applied 
Biosystems, USA) PCR machine. The PCR touchdown program, used for the 
reaction of amplification was as follows – 
1=95.0°; 15:00 min 
2=95.0°; 0:25 min 
3=64.0°; 0:30 min 
4=72.0°; 0:40 min 
5=Go to 2, 4 times 
6=95.0°; 0:25 min 
7=62.0°; 0:30 min 
8=72.0°; 0:40 min 
9=Go to 6, 30 times 
10=72.0°; 5:00 min 
11=6.0° forever 
 
Amplified PCR products were electrophoresed through a 1.5% agarose gel. 
PCR products were purified with Shrimp alkaline phosphatase and Exonuclease 
I (Thermo Fisher Scientific, USA). Sanger sequencing reactions were per-
formed from purified PCR fragments using BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, USA). Reactions were processed on the 
ABI3730xl instrument.  
Sequence reads were analyzed using the Sequence Scanner v1.0 of Applied 
Biosystems and aligned to the GenBank human reference genome sequences of 
COL1A1 (gDNA NG_007400.1, complementary DNA (cDNA) NM_000088.3) 
and COL1A2 (gDNA NG_007405.1, cDNA NM_000089.3). Sequence analysis 
and pathogenic variant identification was performed with Mutation Surveyor 
DNA variant analysis software of Softgenetics (USA). We focused on non-
synonymous and splice-site variants absent from the publicly available normal 
datasets (including dbSNP135 and the 1000 Genomes Project) (Consortium, 
2015; Sherry et al., 2001). We used the PolyPhen-2, SIFT, Alamut Visual 
software of Interactive Biosoftware, Variant Effect predictor (Ensemble), 
MutationTaster software tools to predict the functional effects and pathogenicity 
of pathogenic variants (Adzhubei et al., 2010; Kumar et al., 2009; Schwarz et 
al., 2010). Variants absent from the Osteogenesis Imperfecta pathogenic variant 
database were considered novel (http://www.le.ac.uk/ge/collagen/) (Dalgleish 
1998). Pathogenicity of the novel genetic variants was interpreted using 
guidelines and standards of the joint consensus recommendation of the ACMG 




4.2.2.2. Sequencing analysis of the 5’UTR region of the IFITM5 gene  
(Paper IV) 
The presence of a c.–14C>T variant was controlled in a screened cohort of 90 
unrelated patients negative for the COL1A1/2 pathogenic variants. Only one 
patient was suspected previously to have OI type V, due to significant visible 
HPC.  
DNA samples were amplified using a PCR with a specially designed primer 
pair covering the 5’UTR region and exon 1 of the IFITM5 gene: IFITM5_F  
5’-GGCTCCTGTACATCCCTGAA-3’ (forward) and IFITM5 _R 5’-GTGTGA 
GGGCTGTGTGGG-3’ (reverse). 
The PCR amplification, PCR products purification, Sanger sequencing 
reaction performance and processing was performed as stated in the section 
4.2.2.1. Sequence reads were aligned to the RefSeq sequence of the IFITM5 
(NM_001025295.1). Sequence analysis and pathogenic variant identification 
was performed with Mutation Surveyor DNA variant analysis software 
(Softgenetics, USA).  
 
 
4.2.3. Analysis of de novo OI (Paper III) 
Unrelated subjects diagnosed with OI types I–IV and harboring COL1A1/2 
pathogenic variants have undergone a comparative genotype and phenotype 
analysis of the de novo and inherited OI cases. The cohort included the youngest 
affected proband of every kindred from Estonian (27), Vietnamese (57) and 
Ukrainian (62) OI families.  
The inheritance pattern for every kindred was determined based on OI 
family history. Cases with multiple affected individuals across different gene-
rations were considered as having inherited OI. Cases without a previous OI 
history were considered as de novo. Sequencing analysis in parents was per-
formed in order to verify the inheritance pattern of de novo pathogenic variants.  
The absence of pathogenic variants harbored by subjects with de novo OI 
was checked for and confirmed in all available parents. The total number of 
parent-child trios was 45. The total number of parent-child duos, i.e. where only 
one parent was available, was 29. No samples of relatives were available for 8 
of the subjects, all of which harbored heterozygous variants. In cases where the 
parents’ DNA samples were not obtained and a negative OI history in the 
family was determined from patients’ words, a likely de novo state of the dis-
order was assumed. Afterwards, correlations between pathogenic variant nature, 





4.2.4. Genotype-phenotype correlations (Paper II) 
OI skeletal and extraskeletal manifestations were compared with the mutated 
genes and the type of collagen defect to determine genotype-phenotype corre-
lations. We have investigated associations based on the following clinical and 
phenotypical features: OI type (I, III, IV), scleral hue (blue), mobility (wheel-
chair, walking with support, walking independently, immobile), deformities 
(upper limb, lower limb, spine, chest) and fracture number (total and per year). 
Current phenotypic traits were correlated with the following characteristics of 
genotypes: type of the collagen defect (qualitative or quantitative), mutated 
gene (COL1A1, COL1A2, and non-collagen), Gly and Gly to Ser substitutions. 
Also, we have tested associations with the above listed phenotype features with 
qualitative and quantitative OI type I separately. 
 
 
4.2.5. Interfamilial variability analysis (Paper V) 
The study included 81 families, who harbored 62 different COL1A1/COL1A2 
pathogenic variants, which appeared to be independently reported in the OI 
variant database before by various authors. Families were grouped according to 
the following criteria: harbored OI pathogenic variant; clinical OI type reported 
in affected individuals from both UT OI database and Dalgleish’s OI database 
(http://www.le.ac.uk/ge/collagen/) (Dalgleish 1998). Associations between 




4.2.6. Intrafamilial variability analysis (Paper V) 
Intrafamilial variability analysis was performed in 64 families harboring 
COL1A1/2 pathogenic variants with OI diagnosed in two or more generations. 
Sequencing analysis of the COL1A1/2 genes in the families was performed with 
Sanger sequencing. Affected family members from families with huge intra-
familial variability underwent the previously described whole exome sequencing 
(WES) (Maasalu et al., 2015). 
Phenotypical variability was underlined by increasing progress of the OI 
phenotype severity patterns (i.e. OI symptoms with every younger generation) 
or decreasing of OI severity (i.e. OI symptoms dissolve in every younger 
generation). Severity of OI phenotype was evaluated via main OI symptoms: 
number of fractures; age of the first fracture; limb, rib cage and spine deformity 
degree; mobility status; presence of bluish sclera hue; hearing loss severity and 
age of hearing loss start. Phenotype variability was also explored in siblings 
from the same generation of one family with and without OI history. Intra-
familial diversity was identified via the presence of different OI types in the 
members of the same OI family. Only interviewed patients were counted, as the 
OI types of any unavailable patients was not registered. Correlations between 
genotype and degree of intrafamilial diversity were checked. 
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4.2.7. Statistical analysis 
Percentage differences were used to assess the distribution of COL1A1/2 
pathogenic variants in Estonian and Ukrainian OI cohorts and compare them to 
other studied OI populations. The Shapiro-Wilk’s test was used to check the 
normality of continuous variables. Normally distributed continuous data was 
presented as the mean and standard deviation (SD); continuous data lacking 
normal distribution is presented as median and range. The Student’s t-test was 
used to compare normally distributed continuous data, and the Mann-Whitney 
U test was used to compare data without normal distribution. The categorical 
data was expressed as percentages. The significance of associations between the 
genotype and phenotype manifestations was tested using the Fisher’s χ2-test for 
categorical variables. P-values less than 0.05 were considered to be statistically 
significant. All statistical analyses were preformed using R v3.3.2. software (R 
Team, Austria) (Chen et al., 2012). The threshold of statistical significance was 




Informed written consent was collected from all subjects and controls, or their 
legal representatives, prior to their participation in the study. Additional written 
approval was collected to use the pictures and x-rays as illustrative materials in 
publications. The study was conducted in accordance with the Helsinki Decla-
ration and authorized by the Ethical Review Committee on Human Research of 
the University of Tartu (Estonia) (Permit no. 221/M-34), the Ethical Review 
Board of Hue University Hospital (Vietnam) (approval No. 75/CN-BVYD) and 
the Sytenko Institute of Spine and Joint Pathology of the Ukrainian Academy of 
Medical Sciences (Ukraine).   
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5. RESULTS 
5.1. Spectrum of the COL1A1/2 pathogenic variants  
in the Estonian OI population (Paper I) 
COL1A1/2 sequencing analysis with Sanger sequencing highlighted OI 
causative pathogenic variants in 86.67% (26/30) of Estonian OI patients. 
COL1A1 and COL1A2 pathogenic variants were observed in 76.92% (20/26) 
and 23.08% (6/26) of patients respectively (Figure 11). Discovered collagen 
type I pathogenic variants are represented in Table 3. Half of the discovered 
pathogenic variants were novel, previously undescribed in the OI variant 
database. (http://www.le.ac.uk/ge/collagen/). Pathogenicity classification of the 
novel genetic variants is represented in Table 3.1. 
Twenty-five pathogenic variants were AD. Only eight patients did not have 
previous OI history in the family. One patient (EE07) harbored a recessive 
COL1A1 pathogenic variant. Pathogenic variants were not present in healthy 
parents, which underlined the de novo nature of the pathogenic variants in 
existing patients.  
 
Figure 11. Diagram of collagen type I pathogenic variant distribution for Estonian OI 
patients. (a) Percentage of patients with COL1A1/2 pathogenic variants vs patients 
negative for collagen I pathogenic variants. (b) Percentage of pathogenic variants in the 
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LoF pathogenic variants were present in 69.23% of Estonian OI patients 
(18/26), 16 in the COL1A1 and two in the COL1A2 gene (Figure 12). Splice site 
pathogenic variants composed 46.15% (12/26), 10 and two in COL1A1 and 
COL1A2 respectively. One patient had deletion in the intron-exon 34 region of 
the COL1A2 gene (EE30). Six out of 26 patients (23.08%) harbored COL1A1/2 
nonsense pathogenic variants. 
DN pathogenic variants were observed in 30.77% of patients (8/26). Four 
were observed in both COL1A1 and COL1A2 genes. Gly substitutions were 
indicated in seven cases (COL1A1 – 4, COL1A2 – 3). In four patients Gly to Ser 
substitutions were confirmed (Figure 12). 
Figure 12. (a) Spectrum of pathogenic variants of COL1A1/2 genes in Estonian OI 
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(b) Types of the pathogenic variants in the COL1A1 gene (n=20)
Splice site mutations (n=10)
Nonsense mutations (n=6)
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(c) Types of the pathogenic variants in the COL1A2 gene (n=6)
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Interestingly, patients EE21 and EE22 appeared to be carriers of the identical 
pathogenic variant c.3262G>T (COL1A1). Investigation of pedigree trees 
revealed a relation between ancestors of the families four generations back, of 
which the patients were not aware. Patients EE02 and EE05 were carriers of the 
same splice site pathogenic variant c.1821+1G>A (COL1A1). The pathogenic 




5.2. Spectrum of the COL1A1/2 variants in  
the Ukrainian OI population (Paper II) 
Sequencing analysis of the COL1A1/2 genes in unrelated Ukrainian OI patients 
revealed the presence of AD collagen type I pathogenic variants in 63.83% 
(60/94) (Figure 13a). Out of patients with OI type I 63.89% (23/36); type III 
60.87% (14/23); type IV 69.70% (23/33) harbored collagen type I pathogenic 
variants. The total number of pathogenic variants was 63 because double 
pathogenic variants in the COL1A1/2 genes were found in patients UA08 and 
UA85. In addition, a compound heterozygous pathogenic variant in the COL1A1 
gene was confirmed in patient UA55. The discovered pathogenic variants are 
  
Figure 13. (a) Percentages of the families of Ukrainian OI study cohort with and 
without COL1A1/2 pathogenic variants (n=94). (b) Distribution of pathogenic variants 
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(b). Distribution of variants in the
Ukrainian study cohort between the
COL1A1 and COL1A2 genes (n=63).















Forty-eight out of the 63 pathogenic variants (76.19%) were located in the 
COL1A1 gene. Fifteen out of 63 (23.81%) pathogenic variants altered the 
COL1A2 gene (Figure 13b). Twenty seven out of 63 (42.85%) (20 in COL1A1; 7 
in COL1A2) pathogenic variants were novel and unreported in the OI collagen 
type I variant database previously. A pathogenicity evaluation of the novel 
variants is represented in Table 4.1. Thirty one out of 63 (49.21%) were DN 
pathogenic variants, 32 out of 63 (50.79%) were LoF pathogenic variants 
(Figure 14a). Out of DN pathogenic variants 58.06% (18/31) and 41.94% 
(13/31) were located in the COL1A1 and COL1A2 genes respectively. Twenty 
four out of 31 (77.42%) DN pathogenic variants were Gly substitutions (58.33% 
(14/24) COL1A1; 41.67% (10/24) COL1A2). Gly to Ser substitutions were 
present in 45.83% (11/24%) out of them (7 COL1A1; 4 COL1A2) (Figures 14b–
14d). Two patients had missense non-Gly substitution in the C-terminal 
propeptide of collagen α1 (COL1A1): UA21 c.3655G>GT (p.(Asp1219Tyr)) 
and UA71 c.4356G>GC (p.(Gln1452His)). Thirty out of 32 (93.75%) of LoF 
pathogenic variants were in COL1A1 gene. Twelve out of 32 (37.50%) were 
frameshift pathogenic variants (91.67% (11/12) in COL1A1; 8.33% (1/12) 
COL1A2). 34.38% (11/32) were splice site pathogenic variants (9 COL1A1; 1 
COL1A2). 31.25% (10/32) of LoF pathogenic variants were nonsense patho-


























































































































































































































































































































































































































































































































































































































































































































































   










   
   















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3. Phenotypical and genotypic signatures in de novo and 
inherited COL1A1/2 pathogenic variants (Paper III) 
Etiology of the OI causative pathogenic variant was analyzed in 146 OI cases of 
Estonian, Ukrainian and Vietnamese origin harboring COL1A1/2 pathogenic 
variants.  
Eighty-two (56.16%) patients appeared to be de novo cases of OI in their 
families. Estonian (EE) OI patients had 10/27 (37.04%) de novo cases; 
Ukrainian (UA) 36/62 (58.06%); Vietnamese (VN) 36/57 (63.16%) (Figure 15, 
Table 5). 
Seven patients were carriers of compound heterozygous pathogenic variants, 
so the total number of analyzed pathogenic variants was 153.  
 
5.3.1. Phenotypical characteristics and OI manifestations  
in COL1A1/2 de novo pathogenic variants  
We have found strong correlations between OI type and proportion of de novo 
pathogenic variants (p=0.0002) (Table 5). The number of patients with OI type 
I, III and IV were almost even: OI type I (26.83%), OI type III (35.36%) and OI 
type IV (36.59%). Among inherited OI cases OI types were distributed as 
follows: OI type I – 45.31%, OI type III – 7.81%, and OI type IV – 46.88%. OI 
type I and OI type IV were more prevalent among inherited OI cases compared 
to de novo OI. De novo variants composed 85.29% of the OI type III cases 
(Figure 16). 













Proportion (%) of de novo pathogenic variants by population
60 
 
Analysis of DI, hearing loss and sclera hue did not show any associations with 
the etiology of the pathogenic variants. Out of the de novo cases 80.49% had 
normal hearing and 84.38% had blue sclera. Among inherited OI cases, blue 
sclera composed 90.24% and normal hearing was spotted in 95.31% of patients. 
DI was found in 58.54% of de novo and 54.69% of inherited OI cases. 
The total fracture number (p=0.0224), as well as the number of fractures per 
year (p=0.0014) were significantly greater in de novo OI cases (means of 21.96 
and 1.74, respectively) compared to inherited OI (means of 12.50 and 1.07, 
respectively) cases. In cases of de novo OI type III (mean 2.35, p=0.0023) the 
number of fractures per year was significantly higher compared to inherited OI 
type III. Differences remained in the number of fractures per year (mean 0.95). 
Differences in the fracture number per year of de novo and inherited type I and 
IV cases were insignificant. 
 
Figure 16. (a) Distribution of OI types in collagen type I de novo and inherited OI. (b) 
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Table 5. Characteristics of de novo and inherited OI cases. EE – Estonian, UA – Ukrainian, VN –
Vietnamese populations. 
All patients De novo % Inherited % Total % P-value 
Total 82 56.16% 64 43.84% 146 100% 
EE 10 37.04% 17 62.96% 27 18.49% 
UA 36 58.06% 26 41.93% 62 42.47% 
VN 36 63.16% 21 36.84% 57 39.04% 
Sex 
Males 34 49.28% 35 50.72% 69 47.26% 
0.1338 
Females 48 62.34% 29 37.66% 77 52.74% 
OI Type 
OI I 22 (26.83%) 43.14% 29 (45.31%) 56.86% 51 34.93% 
0.0002 
OI II 1 (1.22%) 100.00% 0 0.00% 1 0.69% 
OI III 29 (35.36%) 85.29% 5 (7.81%) 14.71% 34 23.29% 
OI IV 30 (36.59%) 50.00% 30 (46.88%) 50.00% 60 41.09% 
Fractures        
Number of total 
fractures 
(mean) 
21.96 12.50 17.81 0.0224 
Fractures per 
year (mean) 
1.74 1.07 1.45 0.0014 
Genotype 
COL1A1 58 (65.91%) 52.25% 53 (81.54%) 47.75% 111 72.55% 
0.0360 








12 37.50% 20 62.50% 32 
 
Splice site 16 50.00% 16 50.00% 32 
Missense 60 (68.18%) 67.42% 29 (44.62%) 32.58% 89 58.17% 
Gly 48 68.57% 22 28.57% 70 0.0139 




       
Transitions 54 56.84% 41 43.16% 95 62.09% 
0.6039 Transversions 24 63.16% 14 36.84% 38 24.84% 
Indel 10 50.00% 10 50.00% 20 13.07% 
62 
5.3.2. Proportion, functional type and architecture of de novo and 
inherited COL1A1/2 pathogenic variants.  
There was a significant association between mutated gene and etiology of the 
pathogenic variants. (p=0.0360). COL1A1 pathogenic variants composed 65.91% 
(58/88) and 81.54% (53/65) of de novo and inherited cases respectively (Figure 
17 a, Table 5). De novo variants composed 52.25% of identified COL1A1 patho-
genic variants. COL1A2 pathogenic variants composed 34.09% (30/88) and 





Figure 17. (a) Distribution of COL1A1 and COL1A2 pathogenic variants for de novo
and inherited OI. (b) Functional types of pathogenic variants in de novo and inherited 
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5.4. OI type V in Ukrainian and Vietnamese OI populations 
(Paper IV) 
We screened 90 unrelated OI patients for the presence of a heterozygous  
c.–14C>T variant in the 5’UTR of the IFITM5 gene typical for OI type V. 
According to clinical examination, OI type V was suspected only in one patient. 
Nevertheless, we have discovered four more cases of OI type V, who had an 
identical pathogenic variant. Three patients were Ukrainian and one patient was 
of Vietnamese origin. In the Estonian OI cohort we have not discovered any 
carriers of the 5’UTR IFITM5 gene pathogenic variant. In one case (patient 2), 
the pathogenic variant was inherited and the previous family history of OI was 
registered. The pathogenic variant was confirmed in an affected mother (pa-
tient 3). Prevalence of OI type V among cohort of OI patients from TU OI 
database was 1.48% (5/337) (Table 6). 
Four patients had signs of HPC and dislocation of the radial head. In three 
patients, interosseous membrane calcification and metaphysial radiodense bands 
were discovered. Three patients had bluish sclera. Patient 1 had brittleness of 
the teeth of an unknown etiology and hearing loss since they were 14 years old. 
Patient 2 and 3 showed joint laxity. The number of fractures was 0.5 to 2.3 per 
year, with highest amount in patient 4. Deformities of limbs were mostly mild. 
Three patients had chest and spine deformities. Patient 1 was immobile. All 
patients were shorter than normal (Table 6).  
Functional type of the collagen type I defect correlated with the etiology of the 
pathogenic variant (p=0.0063) 68.18% of the DN pathogenic variants were de 
novo. However, 55.38% of LoF pathogenic variants were inherited (Figure 
17 b). Of the de novo pathogenic variants, 54.55% were Gly substitutions (Figure 
17c). Out of DN pathogenic variants (n=89), 67.42% were de novo (n=60) 
(Table 5). Out of Gly and Gly to Ser substitutions, 68.57% (48/70) and 61.54% 
(24/39) arose de novo respectively. There were more Gly substitutions among 
de novo OI cases, compared to inherited (p=0.0139). De novo variants 
composed 43.75% (28/64) of LoF pathogenic variants. Half of splice site 
pathogenic variants (16/32) and 37.50% (12/32) of nonsense and frameshift 
variants had de novo etiology (Table 5). The correlation between position of the 
pathogenic variant as well as architecture of the pathogenic variant and its 
etiology was insignificant.  
Nucleotide transitions composed 62.09% (n=95), of which 50.66% were G>A 
pathogenic variants. Transversions composed 24.84% (n=38), among which 
13.07% were G>T pathogenic variants (n=20). Indels arose 20 times, of which 
14 were deletions.  
64 
Table 6. Phenotype characteristics of OI type V patients. 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age 15 4 34 7 5 
Sex m m f f f 
Country Ukraine Ukraine Ukraine Ukraine Vietnam 
Phenotype severe mild moderate moderate mild 
Mimicking classic OI type V I IV IV I 
OI history in the family no yes yes no no 
Hyperplastic callus 
yes, 
extreme yes yes no yes 
Interosseous membrane 
calcification yes yes yes (fibula-tibia) no no 
Radial head dislocation yes yes yes no yes 
Metaphyseal radiodense band NA yes yes no yes 
Hearing loss yes, age 14 no no no no 
Dentinogenesis Imperfecta (DI) 
no, teeth 
brittle no no no 
Sclera hue greyish bluish bluish greyish bluish 
Number of fractures 8 4 26 16 5 
Number of fractures per year 0.5 1 0.8 2.3 1 
Time of the first fracture 1.3 7 months at birth 3 months 2 
First fractured bone femur left femur elbow, femur scapula lower leg
The most frequently fractured 
bone femur femur femur legs lower leg
Pyramidal/bell-shaped chest yes, severe no yes yes no 
Scoliosis yes no yes yes no 
Upper limb long bone deformity yes, mild yes, mild yes no yes, mild 
Lower limb long bone deformity yes yes, mild yes yes, mild yes, mild 
Mobility immobile, 
lying 
walking walking (didn’t 
walk at age 9–14)
walking walking 
Height (Z score) –3.93 0.66 –2.70 –2.83 –1.22 
Birthweight and length 52/3450 51/2500 52/3300 50/2800 NA/2800
Joint laxity no yes yes no NA 
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5.5. Clinical OI types and phenotype manifestations  
in Ukrainian patients (Paper II) 
The study included 143 affected patients from 94 unrelated Ukrainian OI 
families. Males composed 46.15% (66/143) and 53.85% (77/143) were females. 
None of the families were consanguineous. OI history was observed in 38.71% 
(36/94) of the families. Information about one patient was missing, as she grew 
up in an orphanage. Patients were divided according to clinical classification 
into the five following OI types: type I 46.85% (n=67); type III 16.78% (n=24); 
type IV 34.27% (n=49); and type V 2.10% (n=3) (Figure 18a). The age range of 
the studied individuals was 2 months – 65 years (mean age of 19.46±14.38 
years). Half of the patients (54.23%, 77/143) were in the 0–17 (pediatric) age 
group. Clinical characteristics and phenotype manifestations of the studied 
Ukrainian OI patients may be found in Table 7. The median/(range) for the total 
number of fractures per patient was 10.00 (0–300) (type I 5.00 (0–30), type III 
20.00 (1–300), type IV 11.00 (0–60) and type V (median±SD) 12.67±11.72) 
(Figure 18, Figure 19). The number of fractures per year per affected individual 
was 1.32±2.88. The number of fractures divided by OI types was as follows: 
type I 0.50±0.43, type III 3.51±6.18, type IV 0.83±1.76 and type V 0.77±0.23 
(Figure 18c). The highest number of fractures was observed in a 35-year-old 
individual with OI type III, who had 300 fractures (lock time May 2016). Only 
4.96% of patients (7/143) did not have fractures, two of them were in the adult 
age group (a 50 year old, type I; a 33 year old, type IV). A positive OI diagnosis 
in patients without bone fractures was based on having a positive OI history, 
skeletal deformities, and/or extraskeletal manifestations. Intrauterine fractures 
were registered in seven affected individuals (type III 30.43%, n=7; type IV 
4.17%, n=2). During delivery 19 affected individuals experienced their first 
fracture (type I 8.96%, n=6; type III 26.09%, n=6; type IV 12.50%, n=6; type V 
33.33%, n=1). 22.70% of patients (n=32) had their first fracture at the age of  
0–1 years; 24.82% (n=35) at the age of 1–2 years; 17.02% (n=24) 3–6 years; 
10.64% (n=15) ≥7years old. Fractures in the tubular bones were the most 
common. 53.73% (n=72) of patients had the highest number of fractures in their 
lower extremities; 22.39%, (n=30) in upper extremities; 17.16% (n=23) in both 
lower and upper extremities. 
Skeletal deformities were observed in 87.23% (n=123) of the patients. 
Patients with type I had mild or no deformities. 81.56% (n=115) had defor-
mities of the lower extremities of varying severity: severe (type III, n=16; type 
IV, n=4; type V, n=1); moderate (type I, n=12; type III, n=7; type IV, n=27; 
type V, n=1); mild (type I, n=33; type IV, n=14). Deformities of upper extre-
mities comprised 65.96% (n=93) of the OI patients. The majority of the patients 
had scoliosis and kyphosis. (77.30%, n=109). Forty-nine (34.75%) patients had 
chest deformities. The majority of patients (74.29%, n=104) were able to 
ambulate independently. Only 12.86% (n=18) needed walking aids; 12.14% 
(n=17) were wheelchair users. Two patients with type III were immobile.  
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Half of the cohort (54.68%, n=76) had DI (type I, 41.79%; type III, 70.83%; 
type IV, 61.22%; type V, 33.33%). Slightly more than a quarter of the patients 
had joint laxity (26.62%, n=37) (type I, 24.24%; type III, 27.27%; type IV, 
26.53%; type V, 66.67%). Contractures were observed in two patients (type I 
and III). 87.32% (n=124) of patients had blue eye sclera (type I, 85.07%; type 
III, 86.96%; type IV, 89.80%; and type V, 100%). Hearing loss of differing 
severity was observed in 22.38% (n=32) of the patients (22.38% were type I 
(n=16), 20.83% were type III (n=5), 22.45% were type IV (n=10) and 33.33% 
were type V (n=1)). Three patients (types I, III and IV) had congenital hearing 
loss. Hearing loss started in 12 patients at the age of 1–10 years; nine patients at 


































































































































































































































































Table 7. Clinical characteristics of the study cohort of Ukrainian OI patients divided by clinical OI 
type. Data is n (%) unless otherwise indicated. SD is standard deviation. 
 OI type I OI type III OI type IV OI type V All OI types
Individuals 67 (46.85%) 24 (16.78%) 49 (34.27%) 3 (2.10%) 143 (100%) 
Families with OI history 
(n=93) 
19 (52.78%) 2 (8.70%) 14 (42.42%) 1 (50%) 36 (38.71%)
Gender Male/Female 35/32 4/20 25/24 2/1 66/77 
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Figure 19. Total number of fractures in Ukrainian OI patient by OI type and age. 

































28 (41.79%) 17 (70.83%) 30 (61.22%) 1 (33.33%) 76 (54.68%)
Blue sclera (yes) 57 (85.07%) 20 (86.96%) 44 (89.80%) 3 (100%) 124(87.32%)
Hearing loss (yes) 15 (22.38%) 5 (20.83%) 11 (22.45%) 1 (33.33%) 32 (22.38%)











































5.6. Genotype-phenotype correlations (Paper II) 
Analysis of genotype-phenotype correlations in Ukrainian OI cohort has 
revealed clear correlation between OI type and collagen defect. LoF pathogenic 
variants correlated with milder OI, compared to severe OI, which was 
associated with DN pathogenic variants (p=0.007). LoF pathogenic variants in 
the COL1A1 gene were also associated with milder OI, compared to LoF in 
COL1A2 (p=0.003). Correlation between OI type and DN COL1A1 and 
COL1A2 pathogenic variants was absent (p=0.895) (Table 8). 
Patients harboring LoF pathogenic variants had significantly less fractures, 
compared to carriers of the DN OI pathogenic variants (p=0.0247). More severe 
skeletal deformities were observed in patients with DN pathogenic variants, 
compared to those with LoF pathogenic variants (p=0.001; p=5.80e–05; 
p=2.37e–05; p=2.0e–04). Type I patients with DN pathogenic variants had more 
severe deformities of lower extremities and spine compared to type I patients 
with LoF pathogenic variants (p=0.022, p=0.029). Gly substitutions in COL1A2 
gene correlated with more severe chest and spine deformities, compared to Gly 
substitutions in the COL1A1 gene (p=0.010, p=0.004). Patients with DN 
pathogenic variants were less mobile than patients with LoF pathogenic variants 
(p=0.023). DN pathogenic variants in the COL1A2 were more associated with 
reduced mobility compared to DN pathogenic variants in the COL1A1 
(p=0.038). DI and hearing loss lack correlation with the genotype in Ukrainian 
OI cohort. However, blue sclera was associated with collagen type I pathogenic 
variants (p=0.011) (Table 8). 
The total number of analyzed, unrelated patients from the Estonian, 
Ukrainian and Vietnamese populations was 238. Distribution of OI types was as 
follows: OI type I – 87 (36.56%), OI type II – 1 (0.42%), OI type III – 66 
(27.73%), OI type IV – 80 (33.61%), OI type V – 4 (1.68%). 
COL1A1/2 pathogenic variants were harbored in 144 individuals. Among 
collagen-related OI cases, OI types were distributed as follows: OI type I-51 
(35.42%), OI type II-1 (0.69%), OI type III-34 (23.61%), and OI type IV-58 
(40.28%). OI type correlated with the presence of the collagen type I pathogenic 
variants (p-value 0.0039). OI types I and IV were more common for collagen-
related OI, than for non-collagen OI. OI type also correlated with an altered 
COL1A1 or COL1A2 gene (p-value 0.0013) and collagen defect DN (qualitative) 
or LoF (quantitative) (p-value 0.0003) (Table 9). The presence of blue sclera 
correlated with collagen type I pathogenic variants (p-value 4.216e–05) and DI 
was associated with a qualitative collagen type I disorder (p-value 0.0008) 
(Table 9). The number of total fractures and fractures per year correlated with 
presence of the collagen type I pathogenic variant, affected gene and collagen 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 9. Relationships between collagen I pathogenic variants and phenotypes in cohort of 238 OI 
patients from UT OI database. Statistically significant p-values are marked with *. Data are n. 
Collagen I Gene Defect 
Collagen 
Non-
collagen COL1A1 COL1A2 COL1A1/2 DN LoF DN/LoF
Type 
OI I 51 36 43 7 1 20 30 1 
OI II 1 0 1 0 0 1 0 0 
OI III 34 32 16 18 0 29 5 0 
OI IV 58 22 42 13 3 32 25 1 
OI V 0 4 – – – – – – 
Total (n=238) 144 94 102 38 4 82 60 2 




sclera (n=236) 132/11 67/26 93/8 35/3 4/0 72/9 58/2 2/2 






















(n=236) 25/119 23/69 16/86 6/32 3/1 12/70 12/48 1/1 
p-value 0.1851 0.0279* 0.2578 
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5.7. Inter- and intrafamilial variability (Paper V) 
5.7.1. Interfamilial variability 
Based on phenotype-genotype characteristics, following groups were created: 
monophenotype (i.e. patients, with pathogenic variants, which caused the same 
phenotype), which included mild phenotype (type I), moderate phenotype (type 
IV) and severe phenotype only (type III); and polyphenotype group mild-
moderate phenotype (i.e. patients with OI types I and IV), severe-moderate 
phenotype (i.e. patients with pathogenic variants which caused variable pheno-
types, which included less variable phenotypes (mild-to-moderate (I, IV), 
severe-to-moderate (III, IV)) and more variable phenotypes (opposite (I, III), 
non-lethal (I, III, IV) and mild-to-lethal (i.e. all OI types) (Figure 20). 
Ten out of 62 explored pathogenic variants (17.74%) did not cause pheno-
typical variability and all discovered carriers had developed identical pheno-
types. These pathogenic variants are described as monophenotypic variants in 
Table 10. They included eight pathogenic variants causing only mild OI, two 
pathogenic variants causing only severe OI and one pathogenic variant causing 
moderate OI (Table 10, Figure 21). 
All eight monophenotypic pathogenic variants which caused mild OI, type I 
were located in the COL1A1 gene. Missense pathogenic variants were represented 
with two variants: c.590G>A, p.(Gly197Asp) and c.3766G>A, p.(Ala1256Thr); 
the other six were LoF pathogenic variants. Four of the patients from the UT OI 
database harbored the same frameshift pathogenic variant COL1A1 c.579delT, 
p.(Gly194Valfs*). In the Dalgleish’s database the current pathogenic variant 
was described in 22 patients with OI type I only (Figure 21). 
Two monophenotypic COL1A1 DN pathogenic variants caused only OI type 
III: c.1165G>A, p.(Gly389Ser) and c.742G>A, p.(Gly284Arg). Only moderate 
OI was caused by a COL1A2 DN pathogenic variant c.1630G>A, p.(Gly544Ser). 
A majority of pathogenic variants caused polyphenotypes. Among them were 
variants, which caused the development of less variable phenotype (I, IV and 
III, IV). 
Twenty pathogenic variants caused OI phenotype of mild-to-moderate 
severity, types I, IV. LoF pathogenic variants were represented by 14 variants, 
all in the COL1A1 gene. DN pathogenic variants were represented only with 
Gly substitutions, six in the COL1A1 and two in the COL1A2 genes. 
Nine pathogenic variants caused severe-to-moderate OI, types III, IV. Six of 
the pathogenic variants were located in the COL1A2 gene. 7/9 were DN patho-
genic variants. Two LoF pathogenic variants were both splice site: COL1A1, 
c.2612+6T>C; COL1A2, 792+1G>A. The COL1A2, c.3034G>A, p.(Gly1012Ser) 
pathogenic variant was harbored by a pair of 13-year-old monozygotic twins. 
Both girls had severe OI type III. The patients had severe skeletal deformities, 
DI, white eye sclera and without hearing loss. Their number of fractures was 
moderate (10 and 15). The current variant was described in 25 other patients 
from the Dalgleish’s database, with OI types III and IV. 
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More variable phenotype were represented with three groups: opposite pheno-
types, non-lethal OI and all OI forms, including lethal OI. Three DN pathogenic 
variants in the COL1A2 gene caused opposite phenotypes for OI type I and III: 
c.1072G>T, p.(Gly358Ser); c.2233G>C, p.(Gly745Arg) and c.874G>A, 
p.(Gly292Ser). 
In the non-lethal OI phenotype group, 14 pathogenic variants were repre-
sented with types I, III, IV. 10/14 pathogenic variants were in the COL1A1 gene. 
11/14 variants were DN. Three LoF pathogenic variants: c.1821+1G>A, 
c.1243C>T, p.(Arg415*), c.1128_delT were located in the COL1A1 gene.  
In a group of mild to lethal OI type II, five DN pathogenic variants caused all 
OI types. Among this group only Gly to Ser substitutions were present. Four 
pathogenic variants were in the COL1A1 gene: c.1102G>A, p.(Gly368Ser), 
c.1588G>A, p.(Gly530Ser), c.2299G>A, p.(Gly767Ser) and c.2596G>A, 
p.(Gly866Ser). Only the c.1378G>A, p.(Gly460Ser) pathogenic variant was in 
the COL1A2 gene. The COL1A1 c.2299G>A, p.(Gly767Ser) pathogenic variant 
was identified 35 times in patients reported in the Dalgleish’s OI variant 
database. In three of our patients this variant caused OI types I, IV and III 
(Figure 22). The c.2299G>A pathogenic variant can cause the development of a 
whole range of OI phenotypes of – from mild to lethal. 
We spotted a pattern of interfamilial variability, which was associated with 
the altered gene and type of pathogenic variant defect. Decreased interfamilial 
variability correlated with COL1A1 gene pathogenic variants (p-value=0.001), 
whereas higher phenotypical variability was among carriers of the COL1A2 
pathogenic variants. Also, interfamilial variability was associated with collagen 
defect type (p-value=0.0007). DN pathogenic variants correlated with higher 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.7.2. Intrafamilial variability 
Being a center for OI treatment and research, the Clinic of Traumatology and 
Orthopedics of Tartu University Hospital, has followed up with OI families 
during the last 25 years. Their current work with OI families provided an 
exclusive observation experience of OI phenotype development and variability 
inside families. It was noted, that OI symptom severity changes usually happen 
smoothly in one direction by decreasing or increasing. Intrafamilial diversity 
was underlined with the increase of OI phenotype severity patterns (i.e. OI 
symptoms progress with every younger generation) or a decrease in OI severity 
(i.e. OI symptoms dissolve in every younger generation). Variability of the 
phenotypes among siblings and cousins from the same generation was referred 
to as “no changes in severity” and “changing in severity”. 
Our data shows, that the level of phenotypical variability inside the families 
was lower, compared to variability between unrelated individuals. In total, 
21/64 (32.81%) of the studied families had changes in OI severity throughout 
generations. Diversity of phenotypes between siblings and cousins from the same 
generation composed only 7/68 (10.29%) of the families. Intrafamilial diversity 
was compromised mainly of cases of mild and moderate OI inside one family. 
Polyphenotype, represented with types I, IV, III, were identified in two families. 
In eight families (5 COL1A1, 2 COL1A2, 1 COL1A1/2) decreasing severity 
was confirmed (36.37%) (Table 11, Figure 23). Four of the families had LoF 
pathogenic variants. In 13 families (11 COL1A1, 2 COL1A2) progressing 
severity was spotted (61.90%). Data was collected from two (n=8), three (n=3) 
and four (n=2) generations (Table 11, Figure 23). Nine out of 13 families had 
DN pathogenic variants. Twenty seven out of 43 (62.79%) families lacking 
intrafamilial variability had LoF pathogenic variants.  
 
Figure 22. Patients from the UT OI database, harboring the COL1A1 DN variant 
c.2299G>A, p.Gly767Ser. (a) Type I, (b) Type IV, (c) Type III. 
(a) (b) (c) 
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We identified a correlation between the type of the collagen defect and 
intrafamilial variability (p-value=0.0231). LoF pathogenic variants correlated 
with the absence of intrafamilial variability, whereas families harboring the DN 
pathogenic variant had higher variability. There were no correlation between 
gene and intrafamilial variability (p-value=0.2376). 
The COL1A1 c.3652G>A, p.(Ala1218Thr) pathogenic variant associated 
with “high bone mass OI” was harbored by a family with an increasing OI 
severity. The mother (40 years old) had mild OI (normal height, blue sclera, 
hearing loss, DI, moderate number of fractures, no visible skeleton deformities, 
the ability to move independently). Her son and daughter with different fathers, 
aged 20 and 9 respectively, both had the same pathogenic variant. Both children 
developed DI and had normal height. In addition, the children used wheelchairs 
due to poor bone quality of their lower limbs and an inability of lower limbs 
weight bearing. Both kids had an extreme number of fractures (50–60), grey 




Decreasing OI severity was oppositely underlined in two Estonian families. The 
first family harbored the LoF splice site c.1821+1G>GA pathogenic variant in 
the COL1A1 gene. The first OI generation was represented by a patient with 
severe OI phenotype (short stature, severe skeletal deformities, high number of 
fractures, severe osteoporosis, triangular face, blue sclera, hearing loss). In every 
younger generation, symptoms of OI phenotype dissolved towards mild OI. The 
number of fractures reduced, patients had normal height and only mild skeletal 
deformities were present. The presence of blue sclera and hearing loss remained 
without any changes through upcoming generations. The second family had a 
frameshift LoF COL1A1 pathogenic variant c.1128_delT, p.Gly337Alafs*164. 
Figure 23. Genotypes and intrafamilial phenotypical variability in families with 
collagen-related OI. DN – dominant negative pathogenic variant; LoF – loss-of-function 
pathogenic variant. 
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Members of this family developed polyphenotype (types I, IV, III). All affected 
family members were women with blue sclera, absent DI and without hearing 
loss. In the oldest generation, one patient had a severe OI type III (high number 
of fractures, reduced height, deformities of limbs, scoliosis, disproportion of the 
body. A patient from the second generation had mild OI type I with normal 
height. Two more individuals from the following generations had moderate OI 
type IV (reduced height, numerous fractures). 
 
Table 11. COL1A11 and COL1A22 pathogenic variants discovered in OI patients with 








Pathogenic variants discovered in OI patients with decreasing OI severity in 
families 
1 c.1821+1G>A COL1A1 Splice site LoF – 
2 c.750+2T>A COL1A1 Splice site LoF – 
3 c.858+1G>A COL1A1 Splice site LoF – 
4 c.1128_delT COL1A1 Frameshift LoF p.Gly377Alafs*164 










7 c.3305G>T COL1A2 Missense DN p.Gly1102>Val 
8 c.1072G>T COL1A2 Missense DN p.Gly358Ser 
Pathogenic variants discovered in OI patients with progressing OI severity in 
families 
1 c.3217G>A COL1A1 Missense  DN p.Gly1073Ser 
2 c.2362G>A COL1A1 Missense DN p.Gly788Ser 
3 c.3652G>A COL1A1 Missense DN p.Ala1218Thr 
4 c.1057G>T COL1A1 Missense DN p.353G>G/C 
5 c.2560G>A COL1A1 Missense DN p.Gly854Ser 
6 c.2461G>A  COL1A1 Missense DN p.Gly821Ser 
7 c.2461G>A COL1A1 Missense DN p.Gly821Ser 
8 c.2314G>A COL1A2 Missense DN p.Gly772Ser 
9 c.982G>A COL1A2 Missense DN p.Gly328Ser 
10 c.658C>T  COL1A1 Nonsense LoF p.Arg220* 
11 c.495T>A  COL1A1 Nonsense LoF p.Tyr165* 
12 c.1816_delG COL1A1 Frameshift LoF p.Ala606Leufs* 










Pathogenic variants discovered in OI patients without changes in OI severity 
within families 
1 c.505G>A* COL1A1 Missense  DN p.Glu169Lys 
2 c.1A>C COL1A1 Missense DN p.Met1Leu 
3 c.3223G>A COL1A1 Missense DN p.Ala1075Thr 
4 c.959G>A COL1A1 Missense DN p.Gly320Asp 
5 c.1102G>A COL1A1 Missense DN p.Gly368Ser 
6 c.1165G>T  COL1A1 Missense DN p.Gly389Cys 
7 c.977G>A COL1A1 Missense DN p.Gly326Asp 
8 c.2005G>A COL1A1 Missense DN p.Ala669Thr 
9 c.2362G>A COL1A1 Missense DN p.Gly788Ser 
10 c.2299G>A COL1A1 Missense DN p.Gly767Ser 
11 c.3766G>A  COL1A1 Missense DN p.Ala1256Thr 
12 c.1009G>A COL1A2 Missense  DN p.Gly337Ser 
13 c.1009G>A COL1A2 Missense DN p.Gly337Ser 
14 c.1630G>A COL1A2 Missense DN p.Gly544Ser 
15 c.1009G>A COL1A2 Missense DN p.Gly337Ser 
16 c.1964G>T COL1A2 Missense DN p.Gly655Val 
17 c.579_delT COL1A1 Frameshift LoF p.Gly194Valfs*71 
18 c.2821_delG COL1A1 Frameshift LoF p.Gly941Valfs*167 
19 c.2393_dupC COL1A1 Frameshift LoF p.Gly800Argfs*5 
20  c.2523_delT COL1A1 Frameshift LoF p.Gly842Alafs*266 
21 c.630_delG COL1A1 Frameshift LoF p.Glu210Aspfs*3 
22 c.2523_delT,  COL1A1 Frameshift LoF p.Gly842Alafs*266 
23 2093_2110_dup COL1A2 Frameshift LoF p.Leu699_Leu704dup 
24 c.1897G>T* COL1A1 Nonsense LoF p.Glu633* 
25 c.2089C>T COL1A1 Nonsense LoF p.Arg697* 
26 c.3262G>T* COL1A1 Nonsense LoF p.Gly1088* 
27 c.3262G>T* COL1A1 Nonsense LoF p.Gly1088* 
28 c.1081C>T COL1A1 Nonsense LoF p.Arg361* 
29 c.3076C>T COL1A1 Nonsense LoF p.Arg1026* 
30 c.1243C>T COL1A1 Nonsense LoF p.Arg415* 
31 c.3807G>A COL1A1 Nonsense LoF p.Trp1269* 
32 c.2179C>T COL1A1 Nonsense LoF p.Gln727* 
33 c.1821+1G>A COL1A1 Splice site  LoF – 
34 c.1155+2T>G* COL1A1 Splice site LoF – 









36 c.1767+5G>A* COL1A1 Splice site LoF – 
37 c.1354-2A>G COL1A1 Splice site LoF – 
38 c.904-9G>A COL1A1 Splice site LoF – 
39 c.2613+6T>C COL1A1 Splice site LoF – 
40 c.804+1G>A COL1A1 Splice site LoF – 
41 c.103+2T>C COL1A1 Splice site LoF – 
42 c.2614-1G>A COL1A1 Splice site LoF – 
43 
c.2026-
1_2031het dup* COL1A2 Splice site 
LoF 
– 
1 COL1A1 GenBank reference sequence (gDNA NG_007400.1, cDNA NM_000088.3). 




Although the prevalence of OI was estimated as 1/10.000, among some 
researchers, there is still disagreements regarding this number (Marini et al., 
2017). Therefore, some researchers proposed 1/20.000. Health care systems and 
their capacity differ among countries, and even varies between regions of the 
same state, so an accurate number of patients remains unknown (Van Dijk and 
Sillence, 2014). We also admit, that the amount of patients with mild OI might 
be underdiagnosed, as was previously stated (Binh et al., 2017). In addition, in 
some regions due to population genetic differences, OI prevalence might differ 
from worldwide amounts.  
In our study, we have invited all available patients with OI for participation, 
using medical databases and patient registers. We recruited all available OI 
families for the study. Our study is family based. We aimed to cover as many 
OI families as possible from all three countries, based on hospital databases and 
patient organizations. It is also important to note that the number of families 
does not correspond to the number of affected OI individuals. We have 
collected blood samples only from a part of them (i.e. those available during the 
interview); however, some affected family members from dominant OI families 
were not available. We concentrated on the description of genetic pathogenic 
variants in OI families, which we supposed to be the same variant for a whole 
family. Thus, the actual number of covered patients might be even greater due 
to uncaptured, affected family members from families of the UT OI database.  
 
 
6.1. Spectrum of the COL1A1/2 pathogenic variants in the 
Estonian and Ukrainian OI populations (Paper I and II) 
Previous works on OI genetics have shown that collagen type I pathogenic 
variants account for 60–90% of all OI cases (Dalgleish, 1998). Bardai et al. 
have reported results from their sequencing analysis of 598 OI patients from 
487 families of different ethnic origin. The proportion of collagen type I patho-
genic variants in their cohort was 86% (Bardai et al., 2016). The proportion of 
collagen type I pathogenic variants tend to vary in population-based OI studies. 
COL1A1/2 pathogenic variants were present in 87% of EE OI patients. 
According to a study of Finnish OI patients, 90.7% of OI individuals had 
COL1A1/2 pathogenic variants (Hartikka et al., 2004), which is slightly higher 
than what has been observed in Estonian OI population. Results of Estonian 
COL1A1/2 sequencing analysis are similar to the genotype spectrum of the 
Swedish OI patients, which was composed of 87% COL1A1/2 pathogenic 
variants (Lindahl et al., 2015). The proportion of COL1A1/2 pathogenic variants 
in the UA OI cohort (63.83%) was lower than in Northern Europe (e.g. in 
Estonia, Sweden and Finland) (Hartikka et al., 2004; Lindahl et al., 2015). 
However, the UA OI population had a higher percentage of the COL1A1/2 
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compared to Russian and Asian populations. Only 41% of OI patients from 
Yakutia and Bashkortostan (Russia) had COL1A1/2 pathogenic variants 
(Khusainova et al. 2012). Asian populations from Vietnam, Korea and Taiwan 
had reduced amount of COL1A1/2 pathogenic variants: 59%, 52% and 51% 
respectively (Ho Duy et al., 2016; Lee et al., 2006; Lin et al., 2015). Cross-
population analysis of rare disorders in large populous countries is complicated 
as results are often fragmented (Yang et al., 2011; Zhang et al., 2012). At the 
same time, countries with small population sizes and limited sample cohorts 
might have differences in the spectrum of pathogenic variants of rare disorders 
when compared to countries with a higher number of patients. The reason for 
differences in genotypes might hide in the different sample sizes and methods of 
patient recruitment and potential variations in OI genetic epidemiology between 
populations. 
The percentages of pathogenic variants in COL1A1 and COL1A2 genes were 
similar between Estonian (77%, 23%) and Ukrainian (76%, 24%) cohorts, as 
well as Finnish (78%, 22%) and Swedish (79%, 21%) populations (Hartikka et 
al., 2004; Lindahl et al., 2015). Similar results were also observed in a study by 
Pollitt et al. (77%, 23%, n=83) (Pollitt et al., 2006). In the report of Bardai et al. 
the proportion of COL1A1 pathogenic variants was reduced (69%, 31%) (Bardai 
et al., 2016). Interestingly, in a study of 83 OI patients of Turkic and Slavic 
origin from Russia, COL1A2 pathogenic variants were absent (Khusainova et 
al., 2012). These results once more underline differences in genetic epidemio-
logy of collagen-related OI. Population differences of OI might come from 
recessive OI genes, as some unusual alleles might have higher frequencies be-
cause of migration processes and cultural traditions, tolerating consanguinity 
(Cabral et al., 2012; Essawi et al., 2018; Garbes et al., 2015; Kurt-Sukur et al., 
2015; Ward et al., 2002; Willaert et al., 2009). 
It was claimed by Van Dijk et al. (Van Dijk and Sillence, 2014), that OI 
patients of European and American origin harbor more DN pathogenic variants. 
The Estonian OI population can be characterized by a higher proportion of LoF 
pathogenic variants (69%), compared to DN pathogenic variants (31%). A 
similar pattern of collagen defects was found in the Finnish population and 
cohort (LoF – 67%, DN – 33%) of Pollitt et al. (LoF – 65%, DN – 35%) 
(Hartikka et al., 2004; Pollitt et al., 2006). In the Ukrainian OI patients, the 
number of LoF (51%) and DN (49%) pathogenic variants was almost equal. 
Similarly to the Swedish OI cohort, where the amount of LoF and DN patho-
genic variants was 53% and 47% respectively (Lindahl et al., 2015). In 
Taiwanese and Vietnamese OI populations, the percentage of DN pathogenic 
variants was higher 78% than LoF (Ho Duy et al., 2016; Lin et al., 2015).  
Only two Estonian and two Ukrainian patients harbored LoF pathogenic 
variants in the COL1A2 gene, underlining previous results of the reduced 
number of LoF pathogenic variants in the collagen type I α2 chain as affected 
individuals develop very mild phenotype, which oftem remain undiagnosed 
(Hartikka et al., 2004; Lindahl et al., 2015; Pollitt et al., 2006). 
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Gly substitution were the most popular of all DN pathogenic variants. In the 
Estonian cohort they composed 7/8 cases, and in the Ukrainian OI cohort they 
composed 24/31 cases, which supports previous findings. All DN pathogenic 
variants of Estonian patients altered triple helical chain domains (aa residues 
162–1218 α1; aa residues 80–1102 α2) of collagen type 1 α1/2 chains. Only one 
pathogenic variant (patient EE07 with OI Type II) altered the “lethal cluster” 
proposed by Marini et al. (Marini et al., 2007). 
Almost half of the identified pathogenic variants (EE – 50%, UA – 43%) 
were novel and previously unreported in the OI variant database. Out of the 
identified 40 novel pathogenic variants, two were identical in two Estonian 
patients and two were identical in two Ukrainian OI patients. According to 
ACMG pathogenicity criteria, 23 variants were classified as pathogenic, 14 as 
likely pathogenic and three as variants of unknown significance (VUS) (Table 
3.1., 4.1.) (Richards et al., 2015). In the case of the COL1A1, c.505G>A, 
p.Glu169Lys VUS the change appeared to alter a conserved aa, and the current 
position might tolerate the substitution, though, there was evidence of splice site 
changes. However, the current variant is present in gnomAD, and there is lack 
of clinical information of cases carrying this variant. Taking into consideration, 
that the current variant was identified in an individual with mild OI, there is a 
chance that some carriers could have undiagnosed bone fragility. A COL1A2, 
c.2642A>C, p.Glu881Ala VUS was identified in individuals carrying additional 
COL1A1 variants and might have additional shaping effect on bone phenotype. 
Additional functional studies are needed to confirm or oppose the pathogenicity 
of identified uncertain variants.  
Despite the numerous studies on COL1A1/2 pathogenic variants and an 
increasing number of discovered variants, the amount of identified novel patho-
genic variants was still high, which proves the individual nature of OI patho-
genic variants and the ability of OI pathogenic variants to appear in different 
exons of the COL1A1/2 genes (Bardai et al., 2016; Lindahl et al., 2015; Pollitt et 
al., 2006). We believe that these pathogenic variants enrich knowledge about OI 
genotype and improve the understanding of OI genotype-phenotype correlations. 
Some of the novel pathogenic variants alter previously reported positions with 
new variants of substitutions. There is a particular interest to investigate the 
association between OI phenotype and genotypes. We hope that the current 
work enriches the database of OI pathogenic variants and has practical appli-
cations for OI genetic diagnostics. Patients negative for the COL1A1/2 gene 
pathogenic variants will undergo further panel sequencing and WES analysis to 
identify the OI causing pathogenic variant. Patients with contractures will be 
scanned for the presence of a Bruck syndrome diagnosis (PLOD2 and FKBP10 
genes). 
We performed Sanger sequencing of the COL1A1 and COL1A2 genes in 
patients with clinical signs of OI. Sequencing primers were picked far from 
intron-exon splice sites, which allowed for the identification of splice site, 
missense, frameshift and nonsense pathogenic variants in the exons of the 
COL1A1/2 genes. Being a golden standard of sequencing, Sanger method 
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accuracy is about 99.9%. However, it has limitations in identifying the whole 
gene or exon duplications and deletions, which compose 1–2% of the OI popu-
lation. In this way, the number of COL1A1/2 pathogenic variants in studied OI 
patients might be underestimated as the Sanger sequencing did not cover the 
whole COL1A1/2 gene or separate exon deletions. 
 
 
6.2. Phenotypical and genotypic signatures in de novo and 
inherited COL1A1/2 pathogenic variants (Paper III) 
The importance of investigating de novo cases of musculoskeletal disorders lies 
in advancing the understanding of the disorders’ nature, etiology, the risks of 
common and rare bone disorders, promoting of diagnostic approaches, assisting 
family planning and genetic counselling.  
According to the results of our study, 56.16% of unrelated OI patients were 
de novo cases. Steiner et al. proposed that the proportion of de novo OI cases is 
35–60% (Steiner et al., 1993). The amount of de novo cases among Estonian OI 
patients were decreased (37.04%). A lack of de novo OI cases in EE population 
might originate from a lack of severe OI cases, which have greater effect on 
fitness and offspring production. 
The proportion of de novo cases differed between OI types. The vast majority 
(85.29%) of OI type III cases are de novo. Our current results are comparable 
with the percentage of achondroplasia de novo cases, but lower than the 
previously reported proportion of OI type III (Ornitz and Marie, 2002; Jay R. 
Shapiro et al., 2013; Trotter et al., 2005). Phenotype severity characteristics, 
phenotype variability and treatment availability might affect the fitness of 
individuals with OI type III and thus modify the proportion of familial and de 
novo cases in addition to different cohort sizes.  
However, cases of recurrent AD OI were referred to as inherited, the number 
of the de novo OI cases might be slightly overestimated due to a possible 
presence of the gonadal mosaicism (3–5% of parents) (Figure 10) (Chen et al., 
2013; Frederiksen et al., 2016). In addition, in families without available DNA 
samples of parents (n=8) the family history of OI was registered from the 
patient’s word, which might additionally elevate the amount of de novo cases in 
the studied cohort. 
 
 
6.2.1. Phenotypical characteristics and OI manifestations in COL1A1/2 
de novo pathogenic variants 
De novo OI type I, IV and III appeared at relatively similar frequencies (26.83%, 
36.59% and 35.36%, respectively). However, it was expected that in de novo 
cases the amount of type III would be higher than type I and IV, which are more 
common for familial OI. According to data which emerged from our study, 
sporadic OI cases of different non-lethal OI types arise at similar frequencies. 
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However, OI type I and IV are more common among inherited OI cases. 
Another possible explanation might result from under- or misdiagnosis of mild 
OI cases. The absence of OI family history and variability of clinical charac-
teristics might promote complications in OI diagnosis, which can lead to a 
suspicion of child abuse or diagnosis of other skeletal dysplasia.  
The majority of OI patients harbor collagen I pathogenic variants, so a 
comparative analysis of de novo and inherited COL1A1/2 cases is vital for the 
daily practice of health professionals, who work with OI patients without access 
to genetic testing. On practice, predominantly severe OI cases are suspected to 
be de novo OI cases. However, a medical professional might run into de novo OI 
patients with OI type I, III and IV with relatively similar frequency as the main 
differences in OI type distributions come from inherited OI cases. The nature of 
pathogenic variants (i.e. de novo or inherited) does not affect the severity of a 
phenotype itself. However, the severity of a phenotype affects the fitness and 
reproductive decisions of OI individuals. Thus, we can see significant differences 
in type prevalence among de novo and inherited OI cases. We think that these 
factors are crucial for OI diagnosis, family planning and follow up. 
 
 
6.2.2. Proportion, functional type and architecture of de novo and 
inherited COL1A1/2 pathogenic variants  
The amount of de novo pathogenic variants in COL1A1 gene was higher com-
pared to COL1A2. It must be noted, that obviously some of the COL1A2 patho-
genic variants are underdiagnosed due to an absence of OI-related symptoms. 
Therefore, the amount of COL1A2 pathogenic variants in the inherited OI cases 
was also decreased. Patients with light bone fragility in a family might not 
connect it to any special bone disorder, but rather to a family trait and thus lack 
diagnostics. 
Despite a similar distribution of OI types among de novo OI cases, the 
majority of de novo cases were DN pathogenic variants, which correlate with 
more severe OI phenotype. Among inherited OI more than 50% were LoF 
pathogenic variants, which are generally associated with milder OI forms. This 
might result from higher fitness of mild OI. 
There were no differences between the results of our study compared to 
previous works on pathogenic variant architecture. The majority of pathogenic 
variants were G>A transitions in the chain domain of the collagen type I α1 or 
α2 chains. Transitions happen more often because of instability in methylated 
CpG dinucleotides (Acuna-Hidalgo et al., 2016). Highly expressed CG sites are 
the main source of disease-causing pathogenic variants, including OI pathogenic 
variants, which happen prevalently in CpG islands. Further studies might con-
centrate on investigating the overall mutational loading differences between de 
novo and inherited OI cases and its impact on OI phenotype.  
Furthermore, WES has confirmed the presence of a COL1A1 pathogenic 
variant in one more Estonian patient; however, current the current variant  
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was absent from Sanger sequencing data (EE06; COL1A1, c.112del, 
p. p.(Ile38Serfs*36)). Therefore, the overall proportion of COL1A1/2 
pathogenic variants in the Estonia population increased to 90% (27/30). In the 
Ukrainian OI cohort, the nature of a variant previously thought to be pathogenic 
was specified as benign according to updated data reported by other 
investigators (UA29, UA34; COL1A1, c.3223>A, p.(Ala1075Thr)). The current 
pathogenic variant was observed in two patients, so the total number of 
Ukrainian collagen-related OI cases dropped to 60/94 (63.83%) instead of 62/94 
(65.96%). According to latest data, the current polymorphism affects BMD only 
in relation to other OI causing pathogenic variants. However, in the analysis of 
de novo OI cases both patients harboring SNP were implemented into the OI 
collagen cohort. The updated total number of collagen-related pathogenic variants 
was 144. The number of overall de novo cases composed 81/144 (56.25%), the 
amount of Ukrainian de novo cases was 35/60 (58.33%). The influence of the 
update was insignificant for the overall data statistics compared to previous 
results: overall 82/146 (56.16%), UA 36/62 (58.06%). 
 
 
6.3. OI type V in Ukrainian and Vietnamese  
OI populations (Paper IV) 
The percentage of OI type V cases from the general OI population varies from 
five to 10% (Bardai et al., 2016; Y. Liu et al., 2017). In the UT OI biobank less 
than 2% (5/337) of patients had OI type V. There were no patients with OI type 
V among Estonian OI families (n=30), as well as among Palestinian OI families 
(n=49) (Essawi et al., 2018). We suppose that absence of OI type V patients in 
these populations might come from the size of the studied population and 
number of recruited patients.  
The number of OI type V patients in the Ukrainian OI cohort was surprisingly 
high. In contrast, only one patient from the Vietnamese OI cohort had OI type 
V; however, methods for the sequencing analysis and patient recruitment in the 
Ukrainian and Vietnamese cohorts were identical. 
We have observed both de novo and familial OI type V in our patients; 
however, the majority of IFITM5 pathogenic variants were de novo, similarly to 
collagen-related OI (Hanagata, 2016). OI type V does not affect reproduction as 
complications of the disease pass after puberty (Fitzgerald et al., 2013; Rauch et 
al., 2013; Zhang et al., 2013). 
The majority of patients developed HPC, which was in concordance with 
previous results (Hanagata, 2016). Due to the development of HPC, which is 
untypical for classical OI, many of the OI type V patients suffered from a mis-
diagnosis. Patient 1 was previously diagnosed with pseudo osteosarcoma. 
However, a histological analysis of patient 1 has shown a classical OI type V 
mesh-like lamellation pattern, primitive woven bone, inflammation, hyper-
cellular trabeculae and small cartilaginous islands in the HPC (Cheung et al., 
2007; Rauch et al., 2013).  
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In the study of Liu et al. interconnections between osteosarcoma cells and 
the OI type V pathogenic variant c.–14C>T in the IFITM5 gene were found. 
The current pathogenic variant proceeded apoptosis, inhibited tumor invasion 
and promoted osteogenic differentiation (B.-Y. Liu et al., 2017). The effect of 
the MALEP-IFITM5 protein on osteosarcoma is interesting for both disorders, 
especially in cased of extremely severe HPC. 
Interosseous membrane calcification was described to develop in all patients 
who are at least four years old. In our cohort OI type V patients 4 (7 yo) and 5 
(5 yo) interosseous membrane calcification was absent. Correspondingly, a lack 
of interosseous membrane calcification was observed in Chinese OI type V 
patients older than 4 yo (Rauch et al., 2013; Jay R Shapiro et al., 2013). 
In parallel with OI type V symptoms of atypical mineralization, we have 
noticed classical OI features in OI type V patients from our cohort. Patients 
suffered from bone fragility, numerous minimal trauma fractures, skeletal 
deformities, greyish or bluish eye sclera, joint laxity, hearing loss and teeth 
abnormalities. Previously only one patient with OI type V and hearing loss was 
described (Jay R Shapiro et al., 2013). Teeth abnormalities were common 
features in the cohort of OI type V patients from the study of Kim et al. (11/16) 
(Kim et al., 2013). However, at first sight, these collagen-related manifestations 
might seem obscure in non-collagen OI; interconnections of the MALEP-
IFITM5 and collagen expression were registered in models of OI type V 
transgenic mice and OI type V primary osteoblast cultures (Lietman et al., 2015; 
Reich et al., 2015). Accordingly, classical collagen related OI symptoms in 
patients with OI type V could have arisen because of insufficient collagen 
expression and quantitative collagen defect. However, MALEP-IFITM5 also 
affects bone mineralization, where typical OI V symptoms originate.  
Sequencing analysis ruled out misdiagnoses and confirmed OI type V in 
patient 1. This helped to build up an appropriate strategy for pharmacological 
and surgical treatment. Similarly, in the rest of the revealed cases (Patients 2–5 
with suspected classical OI) the treatment strategy was updated. A more careful 
approach is needed to exclude risks and complications, coming from the 
molecular defect of the IFITM5 5’UTR pathogenic variant. Results of the study 
can be further used to provide family planning for those identified with OI type 
V families and to perform cost-effective and rapid genetic testing of family 
members in following generations in cases of suspected OI. 
Both classical OI and OI type V symptoms varied between patients. Fracture 
numbers ranged from 0.5 to 2.3 per year. Growth retardation had a tendency to 
decrease with age and correlated with the severity of the phenotype charac-
teristics. Despite harboring the same pathogenic variant, phenotype diversity 
was striking. It might underline the presence of additional factors, which may be 
equally important as the IFITM5 gene pathogenic variant, for shaping of the OI 
type V phenotype. Rarity of OI type V complicates the investigation of this OI 
form. A collection of patients’ cases, genetic material and deep phenotyping is 
essential for future research on OI type V. 
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6.4. Clinical OI types and phenotype manifestations in 
Ukrainian patients (Paper II) 
One hundred forty-three OI individuals from 94 Ukrainian families. Almost half 
(46.85%) were affected with OI type I, 16.78% with OI type III and 34.27% 
with OI type IV. Three patients were suspected to have OI type V and were sent 
for further genetic testing of the 5’UTR of the IFITM5 gene. 
Previous works have stated the breakdown of OI type among the Polish OI 
cohort (n=123) as follows: OI type I – 44%, OI type III – 33% and OI type IV – 
21% (Rusinska et al., 2017). In the Russian OI cohort (n=117), the break-down 
was 59% of OI type I, 27% of OI type III, 14% of OI type IV (Yakhyayeva et 
al., 2016). Among our UA OI cohort there was a lower proportion of OI type III 
patients. This might be caused by difficulties in some severely affected OI 
patients to travel to the interview venue. Cross-sectional population studies 
usually lack patients with OI I compared to nationwide register-based investi-
gations. Differences are caused by diagnostic methods and reduced interest of 
the patients. However, in one instance the effective work of a UA patient 
organization (The Ukrainian Association of Crystal People) helped to recruit 
more patients with mild OI.  
Previous works have revealed the distribution of OI types as the following: 
Vietnamese (OI I–31.5%, OI III–31.5%, OI IV–37%); Taiwanese (OI I–58%, 
OI III–7%, OI IV–35%); Chinese (OI I–28%, OI III–38%, OI IV–34%); Israeli 
(OI I–61%, OI III–21%, OI IV–14%); Swedish (OI I–68%, OI III–13%, OI IV–
19%); Norwegian (OI I–77%, OI III–9%, OI IV–11%) and Finnish (OI I–72%, 
OI III–4%, OI IV–20%) (Binh et al., 2017; Hartikka et al., 2004; Lin et al., 
2015; Lindahl et al., 2015). Differences in the proportion of OI types might be 
hidden in numerous factors, including: patient recruitment methods, sample 
sizes, diagnostics, classification and influence of genetic epidemiology. 
The number of fractures per year was in concordance with the Swedish OI 
cohort (type I 0.57±0.68; type III 3.83±9.32; and type IV 1.33±1.38) (Lindahl et 
al., 2015). Lower limbs were the most fractured and deformed body compart-
ments, as was seen in studies on other OI cohorts. It might be connected to 
greater mechanical loading of the lower limbs and their weight bearing function 
(Binh et al., 2017). Two individuals older than 18 yo did not develop any 
fractures. They were positively diagnosed with OI due to other classical OI 
symptoms and a positive OI history in the family. Both patients were negative 
for COL1A1/2 pathogenic variants. Further panel sequencing might reveal a 
genetic cause in these patients. Therefore, it would be particularly interesting to 
the identify causative pathogenic variants in these cases and further investigate 
the reason behind the fracture absence.   
The number of patients (55%) with DI was higher than in the Swedish (25%) 
and Brazilian (27%) OI cohorts, but similar to patients from the Vietnamese 
(61%) and Taiwanese (44%) cohorts (Binh et al., 2017; Brizola et al., 2017; Lin 
et al., 2015; Lindahl et al., 2015).  
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87% had blue sclera, which was in concordance with the Swedish, Brazilian, 
Taiwanese and Vietnamese cohorts (80–90%), despite the fact that the pro-
portion of collagen I related OI cases was different (Binh et al., 2017; Brizola et 
al., 2017; Lin et al., 2015; Lindahl et al., 2015). The reason for the current 
similarities might hide in the grater spread of greyish and bluish sclera in non-
collagen OI patients.  
 
 
6.5. Genotype-phenotype correlations UA cohort (Paper II) 
and general genotype-phenotype correlations in 238 OI 
Estonian, Vietnamese and Ukrainian families  
Genotype-phenotype associations in OI remain a main topic of interest for OI 
researchers. However, these correlations are elusive; previous works have 
identified that COL1A1 pathogenic variants are usually more severe compared 
to COL1A2 (Marini et al., 2007; Mrosk et al., 2018). In a cohort of UA patients, 
we have observed increased number of fractures among patients with DN 
pathogenic variants. Among patients with COL1A2 DN pathogenic variants 
deformities of the spine and chest were more common. LoF pathogenic variants 
caused less severe OI forms. General correlations between OI phenotype severity 
and collagen defect were in concordance with previous studies (Ben Amor et 
al., 2011; Lindahl et al., 2015; Marini et al., 2007). In contrast with Swedish OI 
study, OI patients from UA cohort with LoF OI type I differed by less deformed 
lower limbs and less fractures compared to DN OI type I patients. It supports 
idea, that collagen chain structure is vital for phenotype, compared to collagen 
amount. 
We did not observe correlation between pathogenic variant type and DI. Lack 
of correlation between DI and OI pathogenic variant type might be explained by 
the different non-OI etiology of dental issues in UA OI patients (Ben Amor et 
al., 2011; Lin et al., 2009; Lindahl et al., 2015).  
Similarly to previous works in other cohorts, in UA OI patients blue sclera 
highly correlated with the presence of collagen type I pathogenic variant 
(Lindahl et al., 2015). 
There was no correlation between genotype and hearing loss. None of the 
previous works succeeded to discover connections between hearing loss and 
genotype in OI. In the studied UA cohort, the number of pediatric patients with 
hearing loss was surprisingly high, so identification of non-collagen OI patho-
genic variants in this cohort is of particular interest (Ben Amor et al., 2011; 
Hartikka et al., 2004). 
The majority of OI type I and IV were caused with LoF pathogenic variants, 
whereas DN pathogenic variants were associated with OI type III. Interestingly, 
two patients with DN pathogenic variants had OI type III. Among DN cases, 
seven patients suffered from OI type I. Two of them had Gly substitutions, 
which are usually associated with severe OI. The type of the pathogenic variant, 
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pathogenic variant’s helical location and substituted residue affect the severity 
of the phenotype (Marini et al., 2007; Rauch et al., 2010).  
In the full cohort of the UT OI database, we have observed significant corre-
lations between OI type, presence of a collagen type I pathogenic variant, mutated 
gene and collagen defect.  
There remained correlations between collagen OI and blue sclera. Inte-
restingly, in a 238 patient cohort we were able to observe a correlation between 
DI and defect type of COL1A1/2 pathogenic variant, which was absent from the 
UA cohort. DI was associated with structural collagen defects in several 
previous studies (Biria et al., 2012; Li et al., 2019; Maioli et al., 2019; Majorana 
et al., 2010; Nguyen et al., 2017). Involvement of larger sample cohorts from 
different populations might raise the accuracy of studies on rare disorders.  
However, while the overall impact of COL1A1/2 pathogenic variants on 
phenotype is understood, genotype-phenotype correlations remain an unresol-
ved issue. OI causing pathogenic variants do not explain all nuances of pheno-
type development and additional factors play a role in phenotype shaping. Great 
interest towards overlap of collagen and non-collagen OI phenotypes remains. 
Further research of deep phenotyping and the molecular characteristics of OI 




6.6. Inter- and intrafamilial diversity (Paper V) 
With more information from OI genetic studies genotype-phenotype correlations 
become more conflicted, as patients with identic pathogenic variants can 
developed OI phenotypes of different severity and patients with similar pheno-
types might harbor different phenotypes. Inter- and intrafamilial diversity is 
increasing the difficulty of both family planning and diagnostics. 
 
 
6.6.1. Interfamilial variability 
Eighty percent of COL1A1/2 pathogenic variants harbored by patients from the 
UT OI database showed phenotypic intrafamilial variability. Th cohort of OI 
patients in our study consisted of patients from three populations: Estonia, 
Ukraine and Vietnam. A recent study by Maioli et al. reported lower variability, 
only 31.55% (Maioli et al., 2019). It could be speculated that in contrast to the 
Italian study, we have different populations in our cohort; additionally, we have 
also included publicly available data from the Dalgleish’s database, which is 
comprised of patients from all over the world. 
In the OI variant database patients were diagnosed by different medical 
professionals and a classification bias is present. Monophenotypic variants 
yielded a clear phenotype picture, especially in cases of mild OI, and all reported 
patients were classified with the same OI type. In polyphenotypic pathogenic 
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variants, clinical phenotypes differed between affected individuals. The majority 
of variants caused bordering types of OI, mild-moderate or severe-moderate 
(types I–IV and III–IV).  
The number of observed patients may act as a limitation of the study, as it is 
impossible to catch all carriers of a single pathogenic variant. Data of pheno-
types might be incomplete. More variable pathogenic variants differ with a 
higher number of reported cases in the OI variant database. 
What is more, treatment might have changed the phenotypes of patients 
towards milder forms. Difficulties might be caused by classification bias of OI 
border types (I/IV, III/IV). In some cases, diagnosis might be subjective and 
debatable. Similar issues were reported in case of OI with the IFITM5 Ser40Trp 
pathogenic variant, resembling clinically OI type VI, where a patient suffered 
multiple prenatal fractures, typical for lethal or severe OI, but remained 
fracture-free after birth with normal bone densitometry (Lim et al., 2019).  
However, all these limitations cannot affect the presence of lethal and non-
lethal OI phenotypes among phenotypes caused by a single pathogenic variant. 
These circumstances raise additional challenges for diagnostic procedures and 
disease progression prediction. 
Similarly to previously reported results, according to our data variability 
correlated with the type of collagen defect and gene (Maioli et al., 2019). 
Correlations between the phenotypical variability and the gene could be party 
explained by the near absence of LoF pathogenic variants in the COL1A2 gene 
compared to the COL1A1 gene. Oppositely, the COL1A2 gene dominates a 
number of DN pathogenic variants, especially Gly substitutions.  
LoF pathogenic variants are associated with a lower phenotypical variability 
compared to missense pathogenic variants. These results are confirmed with the 
data from Dalgleish’s database (Dalgleish, 1998). Pathogenic variants reported 
in at least 10 OI cases show that a lack of phenotypical variability is present 
among carriers of the LoF pathogenic variants. LoF pathogenic variants cause 
haploinsufficiency with the following mechanisms: degradation of the abnormal 
collagen type I, inefficient transport of the mRNA to cytoplasm or premature 
termination codons and nonsense-mediated mRNA decay (NMD) (Garnero et 
al., 2009). The reduced amount of collagen I causes mild OI phenotype. Inte-
restingly, in some cases of LoF pathogenic variants in the last exons of the 
COL1A1/2 genes, NMD could escape and abnormal transcripts lead to truncated 
collagen structure, like DN pathogenic variants (Slayton et al., 2000). DN 
pathogenic variants alter the triple helical structure of the collagen and affect 
collagen stability, causing qualitative defect and severe OI. The escape from 
NMD could explain the presence of some LoF pathogenic variants among cases 
of high phenotypical variability. Further functional mRNA studies in indi-
viduals with LoF pathogenic variants of high phenotypical variability might 
help to clarify the current issue. 
Furthermore, it could be proposed that the modification capacity of OI 
phenotypes depends on collagen properties, not its amount, as patients with LoF 
pathogenic variants have lower variability. 
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6.6.2. Intrafamilial variability 
Intrafamilial variability was lower (34.38%), compared to interfamilial variability. 
It could be explained by the higher genetic variations between unrelated indi-
viduals, when compared to members of the same family. We have met the 
majority of affected individuals of the same family during our interviews, and 
our variability estimation is expected to be accurate. Intrafamilial variability, 
however, correlated only with collagen defect type. 
Phenotypical variability can not be disclosed based on differences in treat-
ment on its own. In some cases, mildly affected parents, who did not need treat-
ment, had children with moderate symptoms that were in need of surgical and 
pharmacological treatment. 
According to our data, siblings and cousins from the same generation had 
lower phenotypical variability compared to the variability between different 
generations. However, siblings might have higher genetic variance due to 
recombination, compared to parent-child variance (Visscher et al., 2008). Extra 
differences between parent-child variance might come from de novo pathogenic 
variants (Acuna-Hidalgo et al., 2016; Veltman and Brunner, 2012). 
The progression of OI characteristics in following generations was proposed 
before; however, our study shows that both the increasing and decreasing severity 
of the symptoms are possible (Moraes et al., 2012). For Estonian OI families, 
patterns of OI symptoms dissolve were more common. The Clinic of Traumato-
logy and Orthopedics of Tartu University Hospital treated and followed up with 
Estonian OI families for 25 years. It cannot be excluded, that milder OI forms in 
Estonian OI patients could be supported with regular follow up, medication and 
early deformity corrections, which can prevent fractures and complications. All 
the aforementioned procedures and regular system of management of OI 
patients were absent in Vietnam in Ukraine until recently. At the same time, the 
higher number of families with progressing OI among Ukrainian and Vietna-
mese cohorts might be connected to the dominance of DN pathogenic variants 
in these OI populations, compared to Estonian cohort. 
Further studies are needed to confirm the absence of compound heterozygo-
sity and gonadal mosaicism among studied patients with intrafamilial diversity, 
as these are the main explanations for variability in collagen-related OI (Laine 
et al., 2013; Symoens et al., 2013). However, intrafamilial diversity could be 
also caused by modifier factors (Cutting, 2010; Nadeau, 2001). 
The beneficial outcome of diagnostics and family planning from our study is 
in the prediction of variability risks in upcoming generations for families with 
OI history. In this way, families with LoF pathogenic variants and quantitative 
collagen defect are at a lower risk of phenotypical variability in the case of 
pathogenic variant transduction to following generation. Whereas, families with 
DN pathogenic variants need to be aware of the risks of disease progression in 
their children. 
OI functional studies might underline causes of phenotypical variability. 
Genetic, epigenetic, environmental and complex interactions of all mentioned 
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factors might develop OI phenotype. Follow-up research concentrating on the 
issue of phenotypical variability of OI is needed. In addition to diagnostic and 
family planning benefits, it might have therapeutic potential, as addressing the 
origins of OI phenotypical expressivity may offer a “natural healing force”, 




I. Out of 30 unrelated Estonian OI patients ~90% harbored COL1A1/2 
pathogenic variants. Among the Estonian OI population the amount of LoF 
pathogenic variants was higher (69%) compared to other European OI 
populations. COL1A1 gene was altered in 77% of the cases. DN pathogenic 
variants of Estonian OI patients altered the triple helical chain domain of 
α1 and α2 chains. One pathogenic variant was situated in the lethal cluster 
and caused OI type II. Half of the genetic variants were novel and 
previously undescribed.  
II. Out of 94 screened, unrelated Ukrainian OI patients COL1A1/2 pathogenic 
variants were identified in 63.83%. The number of DN (49.21%) and LoF 
(50.79%) pathogenic variants were almost equal. Novel variants composed 
43% of the identified genetic variants. The distribution of OI types in 
Ukrainian OI patients was as follows: OI type I (46.85%), OI type III 
(16.78%), OI type IV (34.27%) and OI type V (2.10%). Genotype-phen-
otype analysis has supported the dependence of OI phenotype severity on 
the type of collagen I defect.  
III. Slightly more than half (56.16%) of collagen-related OI cases are assumed 
to be de novo, with the highest proportion of de novo cases in the Vietna-
mese population (63.16%) and the lowest among Estonian OI patients 
(37.04%). Mild de novo OI cases are under- or misdiagnosed. There are 
substantial differences between the genotype and phenotype characteristics 
of de novo and inherited OI. Further studies on mutational load differences 
between inherited and de novo OI patients might advance the understanding 
of OI etiology, pathological mechanisms and phenotype development. 
IV. c.–14C>T 5’UTR IFITM5 pathogenic variants were identified in four 
families (five individuals) with OI type V of Ukrainian and Vietnamese 
origin with various phenotype severity, which composed less than 2% of 
the entire studied OI cohort. There were no cases of OI V among Estonian 
OI patients. Results of our study support the presence of classical OI 
features (hearing loss, bluish and greyish sclera, joint laxity and teeth 
abnormalities) in OI V patients in addition to the typical OI V features such 
as abnormal mineralization and HPC. Due to high variation in clinical 
symptoms, we suggest the testing of the 5’UTR of the IFITM5 gene patho-
genic variants in patients who lack OI V features.  
V. OI inter-and intrafamilial variability is associated with genotype characte-
ristics of the OI causing pathogenic variant. We succeeded to form pheno-
typical groups of collagen-related OI based on the genotype-phenotype 
severity scale. We have confirmed the presence of an interfamilial diversity 
pattern, which depends on the mutated gene. Patients lacking diversity 
were harboring pathogenic variants in the COL1A1 gene, whereas patients 
with variable phenotypes were more likely to harbor the COL1A2 patho-
genic variants. Both inter- and intrafamilial diversity correlated with 
collagen I defect type. LoF pathogenic variants lacked diversity in patients 
with mild OI, whereas DN variants were associated with a higher degree of 
phenotype variability. 
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SUMMARY IN ESTONIAN 
Genotüübi ja fenotüübi korrelatsioonidel põhinev Osteogenesis 
Imperfecta perekondade sisene ja vaheline varieeruvus 
Osteogenesis Imperfecta (OI) ehk habraste luude haigus on haruldane geneeti-
line sidekoehaigus. Juba vanast ajast on tuntud OI klassikaliste tunnuste triaad: 
hulgiluumurrud, sinised skleerad ja kuulmislangus. Lisaks on OI peamisteks 
sümptomiteks skeleti deformatsioonid, kolmnurkne nägu, kääbuskasv ja 
Dentinogenesis Imperfecta (DI). OI esinemissagedus on 1/20 000, kuigi erine-
vate OI tüüpide esinemissagedus varieerub. Kergemate OI vormide esinemis-
sagedus on tavaliselt suurem kui raskematel OI vormidel.  
OI esinemise fenotüüpide spekter on väga lai: sinna kuuluvad erinevad vormid 
kergest osteopeeniast kuni letaalsete vormideni. Praegune OI klassifikatsioon 
eristab viit kliinilist OI tüüpi: I–V. Tüüp I on kerge OI väheste luumurdudega, 
oluliste deformatsioonideta ja normaalse kasvuga. Tüüp II on letaalne, mida ise-
loomustavad hulgalised prenataalsed luumurrud, oluline kasvupeetus, rasked 
skeleti deformatsioonid, kolju demineraliseerumine ja respiratoorne puudulikkus. 
Tüüp III on raske OI hulgiluumurdudega ja progreseeruvate skeleti deformat-
sioonide ning kasvupeetusega. Tüüp IV on mõõdukas, mille tunnusteks on nor-
maalne kasv ning luumurdude arv ja deformatsioonide tase on mõõdukad. Tüüp 
V on haruldane OI vorm, mille tüüpilisteks tunnusteks on luudevaheliste memb-
raanide kaltsifitseerumine ja hüperplastilise kalluse tekkimine pärast luumurde. 
Fenotüübid on individuaalsed ning erinevad sama patogeense variandi kandjate 
vahel.  
OI on tuntud peamiselt I tüüpi kollageenistruktuuri või -hulga häirena. Kuni 
90% OI patsientidel esineb geenides autosomaalset dominantset I tüüpi kolla-
geenivarianti COL1A1 ja COL1A2. Ülejäänud ~10% OI juhtudest on seotud 
peamiselt retsessiivsete patogeensete variantidega mitte-kollageeni OI geenides, 
kuigi kliiniliselt meenutavad nende fenotüübid kollageeni patogeensete varianti-
dega patsientide fenotüüpi. OI V tüüpi põhjustab ainult IFITM5 geeni 5’UTR 
variant. Praeguseks on teada 17 erinevat mittekollageeni OI geeni, mille funkt-
sioonid on seotud kollageeni transportimise, voltimise, posttranslatsiooni modi-
fitseerimise, luu mineralisatsiooni ja luurakkude funktsioneerimisega.  
Kollageeni I kvalitatiivne defekt on põhjustatud dominantsest negatiivsest 
(DN) variandist, mis on põhjustatud aminohappe vahetusest kollageeni kolmik-
heeliksis. Kollageeni struktuursed variandid on seotud raskemate OI fenotüüpi-
dega. Kollageeni kvantitatiivsed defektid on seotud ühe alleeli puudulikkusega 
ja sellest tingitud funktsioonikao variantidega (LoF). Kollageenihulga defekt 
assotsieerub kergemate OI vormidega. Genotüüp-fenotüüp korrelatsioone on 
kirjeldatud harva ning peamiselt sama variandiga patsientidel. Isegi ühe pere-
konna liikmetel võib esineda erinev haiguse kliiniline väljendus. Haruldastel 
juhtudel võib sama variant põhjustada isegi nii letaalset kui ka mitteletaalset OI-d.  
Perekondadevaheline ja -sisene varieeruvus on eelnevalt kirjeldatud üksi-
kutel OI juhtudel. OI fenotüübi modifikatsiooni tegurid on jäänud teadmata. 
101 
Fenotüübiline varieeruvus suurendab ala- ja valediagnoosi riski asümptomaati-
liste patsientide korral, takistab haiguse raskuse ning kulu ennustamist nii pere-
konna kui ka haiguse ravi planeerimisel. Fenotüübilise varieeruvuse uurimine 
võimaldab paremini aru saada OI kliinilisest pildist ning aitab seeläbi kaasa uute 
diagnostika- ja ravimeetodite väljatöötamisele. 
 
Uurimuse eesmärgid 
Käesoleva uurimistöö eesmärgiks oli iseloomustada OI perekondade patogeen-
sete variantide profiili, hinnata genotüübi-fenotüübi korrelatsioone koos pere-
konnavahelise ja perekonnasisese varieeruvusega. Sellest tulenevalt olid töö ala-
eesmärgid järgnevad: 
1. Iseloomustada COL1A1 ja COL1A2 patogeensete variantide spektrit Eesti OI 
patsientidel. 
2. Kirjeldada kliinilisi ja molekulaarseid tunnuseid COL1A1 ja COL1A2 pato-
geensete variantidega Ukraina OI perekondade kohordis. 
3. Uurida de novo patogeensete variantide juhtumeid COL1A1 ja COL1A2 
patogeensete variantidega patsientide hulgas. 
4. Selgitada OI V tüübi patogeensete variantide esinemist Eesti, Ukraina ja 
Vietnami OI patsientidel. 
5. Analüüsida võimalikke seoseid perekondadevahelises ja -siseses varieeru-
vuses ning genotüübi mõju COL1A1 ja COL1A2 OI perekondades.  
 
Materjal ja metoodika 
Uuringusse kaasati Tartu Ülikooli Kliinikumi, Traumatoloogia ja Ortopeedia 
Kliiniku OI andmebaasist 238 perekonda, kokku 337 haiget indiviidi. COL1A1/2 
geenide sekveneerimise analüüs teostati 30 Eesti ja 94 Ukraina perekonnas. 
Kliiniliste tunnuste kirjeldamine teostati 143 Ukraina OI patsiendil 94 pere-
konnast. De novo OI analüüs tehti 146 mitteseotud patsiendil, kellel esines 
kollageeni patogeensetest variantidest tingitud OI. OI V tüüpi testiti 90 mitte-
suguluses oleval patsiendil, kellel ei leitud COL1A1/2 patogeenset varianti. 
Perekonnavahelist fenotüübilist varieeruvust uuriti 81 COL1A1/2 patogeensete 
variantidega perekonnas. Perekonnasisest varieeruvust uuriti 64 COL1A1/2 OI 
perekonnas. 
Perekondade haiguse kulu informatsioon koguti intervjuude käigus ja haigus-
lugudest. Kliinilise läbivaatuse ajal hinnati OI kliiniliste tunnuste esinemist. 
Patsiendid klassifitseeriti nende kliiniliste tunnuste avaldumise järgi OI tüüpi-
deks I–V. Vereproovid koguti haigetelt ning nende tervetelt lähisugulastelt 
edasiseteks analüüsideks.  
COL1A1/2 geenide ja IFITM5 geeni 5’UTR patogeensete variantide analüüs 
tehti Sangeri sekveneerimisega verest eraldatud DNAst. Variantide patogeen-
sust ennustati in silico ja ACMG klassifikatsiooni alusel. Patogeenseid variante, 
mis puudusid OI variantide andmebaasist, tuvastati de novo. De novo OI juhtu-
mite analüüsis tuvastati variandi pärimiseviis. Teostati sekveneerimisanalüüs 
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patsiendi vanematel, et kinnitada patogeense variandi puudumist perekonnas 
varasemalt. Analüüsiti patogeense variandi etioloogiat, fenotüübi ning geno-
tüübi tunnuste korrelatsioone. Genotüübi-fenotüübi korrelatsioone testiti OI 
kliiniliste tunnuste ja patogeensete variantide tüüpide vahel. Perekonnavahelist 
varieeruvust analüüsiti isikutel, kelle patogeenne variant esines vähemalt kahel 
mittesuguluses oleval patsiendil Tartu Ülikooli OI andmebaasis või Dalgelish 
OI variantide andmebaasis; hinnati patogeenset varianti põhjustavate tüüpide 
esinemissagedust. Perekonnasisest varieeruvust analüüsiti vastavalt kasvavale 
või kahanevale haiguse ilmestumisele eelmises ja/või järgnevas põlvkonnas. 
Testiti varieeruvuse korrelatsioone kollageeni defektitüübi ja -geeniga.  
Tulemuste võrdlemiseks kasutati kirjeldavat statistikat. Kategooriliste tun-
nuste seoseid testiti Fisher’s χ2-testiga. Shapiro-Wilk’s testi kasutati normaal-
jaotuste määramiseks. Student’s t-testi ja Mann-Whitney U testi abil kontrolliti 
vastavalt normaaljaotusega ja mittenormaaljaotusega pidevate tunnuste seoseid. 
Oluliseks määrati P-väärtus vähem kui 0.05. 
Uuringu teostamiseks olid olemas Tartu Ülikooli Inimuuringute eetikakomi-
tee (Permit no. 221/M-34), Hue Ülikooli (approval No. 75/CN-BVYD), ja 
Harkovi Sõtenko Selja ja Liigeste Patoloogia Instituudi eetikakomiteede load. 
 
Peamised tulemused ja järeldused 
Uurimistöö olulisemad tulemused on järgnevad: 
1. Eesti 30 mittesuguluses olevast OI perekonnast esines ~90% COL1A1/2 
patogeenne variant. Eesti OI populatsiooni hulgas oli LoF variantide arv 
suurim (69%), võrreldes teiste Euroopa populatsioonidega. 77% variantidest 
esinesid COL1A1 geenis. Üks patogeenne variant paiknes kollageeni I 
letaalses klastris ning põhjustas letaalset OI-d (II). Pooled patogeensetest 
variantidest olid uued ja varasemalt kirjeldamata.  
2. Ukraina 94 perekonnast esines COL1A1 variante 63.83% uuritavatest. DN ja 
LoF variantide arv oli praktiliselt sama. 43% variantidest olid de novo. OI 
tüüpide jagunemine oli Ukraina populatsioonis järgmine: OI tüüp I (46.85%), 
OI tüüp III (16.78%), OI tüüp IV (34.27%) ja OI tüüp V (2.10%). Geno-
tüübi-fenotüübi korrelatsiooni analüüs näitas OI fenotüübi raskuse seost 
kollageeni defektitüübiga.  
3. 56.16% kollageeni OI juhtumitest olid de novo. Kõrgeim de novo OI juhtu-
mite osakaal oli Vietnami populatsioonis (63.16%) ning madalaim oli Eesti 
populatsioonis (37.04%). De novo ja pärilikud OI juhtumid erinevad oluliselt 
genotüübi ja fenotüübi alusel. Edasised de novo OI juhtumite uuringud aitavad 
kaasa OI etioloogia, patoloogiliste mehhanismide ja fenotüübi arenemise 
arusaamisele. 
4. c.–14C>T 5’UTR IFITM5 geeni variante tuvastati neljas perekonnas (kokku 
viis patsienti), mis moodustavad vähem kui 2% kogu Tartu Ülikooli OI 
andmebaasi patsientide kohordist. V OI tüübiga patsientid pärinesid Ukraina 
ja Vietnami OI populatsioonidest ning omasid erinevaid fenotüüpe ja raskus-
astet. Eesti OI populatsiooni seas OI V juhtumeid ei olnud. Meie uuringu 
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tulemused toetavad lisaks OI V tunnustele (anomaalne mineralisatsioon ja 
hüperplastlise kalluse kujunemine) ka klassikaliste kollageeni OI sümpto-
mite (kuulmislangus, sinakashallikas skleera, liigeste lõtvus, hammaste ano-
maaliad ja haprus) esinemist V OI tüübiga patsientidel. Kõrge tunnuste 
varieeruvuse tõttu soovitame testida 5’UTR IFITM5 geeni ka neil patsienti-
del, kellel puuduvad selged OI tüüp V tunnused. 
5. OI perekonnasisene ja -vaheline varieeruvus korreleerub genotüübi muutus-
tega OI patsientidel. Meil õnnestus komplekteerida kollageeni OI fenotüübi-
lisi gruppe, toetudes genotüübi-fenotüübi raskusastme skaalale. Leidsime 
perekonnavahelise varieeruvuse mustri, mis sõltub muteerunud geenist. 
Vähema varieeruvusega patsiendid omasid variante COL1A1 geenis võrreldes 
COL1A2 geeni variantide kandjatega, kellel oli suurem fenotüübiline 
varieeruvus. Nii perekonnavaheline kui ka perekonnasisene varieeruvus 
sõltusid kollageen I defektitüübist. LoF patogeensete variantide puhul 
puudus fenotüübiline varieeruvus, kergetel OI juhtumitel DN patogeensete 
variantidega aga assotsieerus kõrgem fenotüübilise varieeruvuse tase.  
 
Kokkuvõttes näitasid käesoleva uuringu tulemused, et suurim osa OI juhtumitest 
nii Eesti kui ka Ukraina populatsioonis on seotud COL1A1/2 patogeensete 
variantidega ning enamus nendest tekivad sporaadiliselt. Vähem kui 2% OI 
patsientidest on V OI tüüp. Kvalitatiivne kollageenidefekt on seotud raskemate 
OI vormidega ning perekonnasisese ja -vahelise varieeruvusega OI patsientidel 
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